TW200925244A - Water-soluble fluorescent material with balanced hydrophilicity and hydrophobicity - Google Patents

Water-soluble fluorescent material with balanced hydrophilicity and hydrophobicity Download PDF

Info

Publication number
TW200925244A
TW200925244A TW097138687A TW97138687A TW200925244A TW 200925244 A TW200925244 A TW 200925244A TW 097138687 A TW097138687 A TW 097138687A TW 97138687 A TW97138687 A TW 97138687A TW 200925244 A TW200925244 A TW 200925244A
Authority
TW
Taiwan
Prior art keywords
group
molecule
backbone
solution
unit
Prior art date
Application number
TW097138687A
Other languages
Chinese (zh)
Inventor
zhi-kuan Chen
Xu Li
Jun-Hong Yao
bei-ping He
Original Assignee
Agency Science Tech & Res
Univ Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res, Univ Singapore filed Critical Agency Science Tech & Res
Publication of TW200925244A publication Critical patent/TW200925244A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00Nanotechnology for materials or surface science, e.g. nanocomposites
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00Manufacture or treatment of nanostructures
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G61/00Macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain of the macromolecule
    • C08G61/02Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G61/00Macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain of the macromolecule
    • C08G61/12Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00Processes of treating or compounding macromolecular substances
    • C08J3/12Powdering or granulating
    • C08J3/16Powdering or granulating by coagulating dispersions
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals
    • G01N33/533Production of labelled immunochemicals with fluorescent label
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/10Organic polymers or oligomers
    • H10K85/111Organic polymers or oligomers comprising aromatic, heteroaromatic, or aryl chains, e.g. polyaniline, polyphenylene or polyphenylene vinylene
    • H10K85/115Polyfluorene; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/14Macromolecular compounds
    • C09K2211/1408Carbocyclic compounds
    • C09K2211/1416Condensed systems
    • HELECTRICITY
    • H10SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
    • H10KORGANIC ELECTRIC SOLID-STATE DEVICES
    • H10K85/00Organic materials used in the body or electrodes of devices covered by this subclass
    • H10K85/10Organic polymers or oligomers
    • H10K85/151Copolymers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Manufacturing & Machinery (AREA)
  • Composite Materials (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Polyethers (AREA)
  • Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)

Abstract

An amphiphilic molecule comprises a backbone and side chains grafted to the backbone. At least three backbone units are hydrophobic and fluorescent and at least one side chain unit is hydrophilic. The weight ratio within the molecule of backbone and side chain units that are hydrophilic to those that are hydrophobic is from about 1: 4 to about 4: 1. To form fluorescent particles, a solution comprising water, an organic solvent and the amphiphilic molecule dissolved in the organic solvent is provided. The concentration of the molecule in the solution is from about 1 to about 1000 CAC, such as about 10 CAC to about 100 CAC, where CAC is the critical aggregation concentration of the amphiphilic molecule. The organic solvent is removed from the solution, thus allowing the amphiphilic molecule to form particles that have a peripheral size from about 10 nm to about 10 microns.

Description

200925244 九、發明說明: 【發明所屬技術領城3 發明領域 5 ❹ 10 15 ❹ 20 本發明係有關於螢光物質,特別是水溶性螢光物質, 及其形成方法。200925244 IX. INSTRUCTIONS: [Technical Field 3 of the Invention] Field of the Invention 5 ❹ 10 15 ❹ 20 The present invention relates to a fluorescent substance, particularly a water-soluble fluorescent substance, and a method of forming the same.

t -jttr J 發明背景 螢光顆粒可用於各種應用。例如,螢光基團係作為, 例如,於許多生化領域,諸如,藥物及基因研究、細胞/微 生物成像、疾病診斷、分析物檢測等,之探測器、標記, 或標籤。因為水性環境係一種普遍環境,所欲地係使螢光 顆粒可溶於水。但是,許多螢光基團係不溶於水。再者, 當螢光基團被曝置於此環境時,其性能可能受環境影響, 且可能不穩定。因此,所欲地係以水溶性外層包封此螢光 基團’使形成之顆粒可溶於水溶液,且使内螢光基團與環 境隔離。 某些傳統之螢光顆粒具有疏水性螢光區段及包封疏水 性區段之親水性或兩親性區段。但是,此等顆粒之缺點係 於水性環境,此等顆粒易聚結/沈澱或崩解,且係不穩定。 因此,性能會隨時間而衰變。因此,所欲者係改良自兩親 性勞光分子形成之螢光顆粒之穩m已知自兩親性分子 形成之顆粒之穩定性可能受其親水性及親疏性間之平衡而 影響。但是’難以預期特定型式之兩親性螢絲合物之親 水性及親疏性㈣對㈣彡成穩定躲係足夠平衡。 5 200925244 【明内3 發明概要 兩親性分子被提供以形成於水中可保持穩定之螢光顆 粒。每一分子包含一主幹及與主幹接枝之側鍵。至少三個 5 主幹單元係疏水性及螢光性,且至少一側鏈單元係親水 性。分子内之親水性之主幹及侧鏈單元對疏水性者之重量 比例係約1:4至約4:1。為形成螢光顆粒,包含水、有機溶劑, ' 及溶於有機溶劑之兩親性分子之溶液被提供。溶液内之此 分子之濃度係約1至約1000 CAC,諸如,約1〇至約100 〇 10 CAC,其中,CAC係兩親性分子之臨界聚結濃度。有機溶 劑自此溶液移除,因而使兩親性分子形成具有約i 〇 n m至約 10微米之外圍尺寸之顆粒。顆粒於水中保持穩定超過6個 月。 因此,於本發明之第一方面,提供一種形成螢光顆粒 . 15之方法。此方法包含提供包含水、有機溶劑,及溶於有機 溶劑之兩親性分子之溶液;自此溶液移除有機溶劑,因而 使兩親性分子形成具有約10 nm至約10微米之外圍尺寸之 〇 螢光顆粒。兩親性刀子包含複數個形成一分子主幹之主幹 單元,及複數個與分子主幹接枝之側鏈,且每一側鏈係以 20至少一侧鏈單元形成。分子内之至少一側鏈單元係親水 性,且至少三個主幹單元係疏水性及螢光性。分子内之親 水性之主幹單元及側鏈單元對疏水性者之重量比例係約 1:4至約4:1,諸如,約3:7至約7:3。溶液内之親水性分子之 濃度係約1至約1〇〇〇 cac,諸如,約10至約100 CAC,其中 6 200925244 CAC係溶㈣之兩親性分子之臨界聚結濃度。溶液可藉由 使水與包含有機_及兩親性分子之先f溶液混合而製 備。有機溶劑可藉由蒸發自溶液移除。溶液可具有舶至約 12之州,且可於約0至約80 °C之溫度,諸如,約4至約7〇 5 ❹ 10 15 ❹ 20 oc。 依據本發明之另-方面,提供依據上述方法形成之水 溶性螢光顆粒。此顆粒可包含對選擇之躲具特定親和力 之配位體。此配位體可選自親和素、生物素、抗體、抗原, 及DNA,且標靶可選自標靶分子 '細胞,及有機體。 依據本發明之另-方面,提供一分子,其係包含複數 個形成一分子主幹之主幹單元,及複數個與分子主幹接枝 之侧鏈,且每一侧鏈係以至少一側鏈單元形成。分子内之 至少-側鍵單元係親水性,且至少三個主幹單元係疏水性 及螢光性。分子内之親水性之主幹單元及側鏈單元對疏水 性者之重量比例係約1:4至約4:1,諸如,約3:7至約7.3。 依據本發明之另一方面,提供一種水溶性螢光顆粒, 其包含於前段落中述之分子。此顆粒可包含對選擇之標靶 具特定親和力之配位體。此配位體可選自親和素、生物素、 抗體、抗原,及DNA,且標靶可選自標靶分子、細胞,及 有機體。 對於前四段落中所述之兩親性分子,主幹單元可包含 芴單元,且側鏈可包含聚乙二醇。主幹單元可包含芳撐基、 雜芳撐基、芳撐基乙烯撐基、雜芳撐基乙烯揮基、芳撑基 乙撐基’或雜芳撐基乙撐基單元,或其衍生物。主幹單元 7 200925244 可包含以烷基、烷氧基、烯基、炔基、烷基矽烷基、芳基 矽烷基芳基、雜芳基、芳基氧、雜芳基氧、烷基硫基烷 基胺基、二烷基胺基、芳基胺基、二芳基胺基、芳基醚、 雜芳基醚、芳基硫醚、雜芳基硫醚、齒素、氰基、硝基、 5羰基、亞硫醯基、磺醯基,或全氟烷基,或包含雜芳基之 胺基取代之單元。主幹單元可包含苯撐基、嗔吩揮基、螺 旋一苟撐基、節并苟撐基、吡啶撐基、二吡啶撐基、咔唑 撐基、印并咔唑撐基、苯并嘍唑撐基,或噁二唑撐基單元, 或其衍生物。至少一主幹單元可與乙烯撐基或乙撐基聯 10接。至少二主幹單元可經由單碳鍵、甲撲基,或選自〇、s、 N、Si ’及p之原子彼此聯接。主幹單元可包含連接二疏水 性及榮光性之主幹單元之可撓性基。可撓性基可為親水性 或疏水ί生。側鏈可包含側鏈單元。側鏈單元可包含聚乙二 醇、聚乙二亞胺、㈣胺、聚乙稀基魏烧酮、聚丙稀酸、 15聚乙稀基醇、聚賴教酸,或其衍生物。至少一側鍵可經由 單碳鍵、單碟鍵、醚基、硫醚基、胺基、亞胺基、石夕烧基、 S旨基、硫顆基、酿胺基,或醯亞胺基與主幹鍵結。兩親性 分子可具有化學式t -jttr J BACKGROUND OF THE INVENTION Fluorescent particles can be used in a variety of applications. For example, fluorescent groups are used, for example, as detectors, labels, or tags in many biochemical fields, such as pharmaceutical and genetic research, cell/microbiology imaging, disease diagnosis, analyte detection, and the like. Since the aqueous environment is a general environment, it is desirable to make the fluorescent particles soluble in water. However, many fluorescent groups are insoluble in water. Furthermore, when a fluorescent group is exposed to this environment, its performance may be affected by the environment and may be unstable. Thus, the desired encapsulation of the fluorescent group by a water soluble outer layer renders the formed particles soluble in aqueous solution and isolates the internal fluorescent groups from the environment. Some conventional fluorescent particles have a hydrophobic fluorescent segment and a hydrophilic or amphiphilic segment encapsulating the hydrophobic segment. However, the disadvantages of such particles are due to the aqueous environment, and such particles tend to coalesce/precipitate or disintegrate and are unstable. Therefore, performance will decay over time. Therefore, the desired one is to improve the stability of the fluorescent particles formed from the amphiphilic work light molecules. It is known that the stability of the particles formed from the amphiphilic molecules may be affected by the balance between hydrophilicity and affinity. However, it is difficult to predict that the hydrophilicity and affinity of the specific type of amphiphilic fluorescene compound (4) are sufficiently balanced with (4) stable stability. 5 200925244 [Mingna 3 Summary of Invention Amphiphilic molecules are provided to form fluorescent particles that are stable in water. Each molecule contains a backbone and side bonds grafted to the backbone. At least three of the backbone units are hydrophobic and fluorescent, and at least one of the chain units is hydrophilic. The ratio of the hydrophilic backbone of the molecule to the weight of the side chain unit to the hydrophobic is from about 1:4 to about 4:1. To form the fluorescent particles, a solution containing water, an organic solvent, and an amphiphilic molecule dissolved in an organic solvent is provided. The concentration of this molecule in the solution is from about 1 to about 1000 CAC, such as from about 1 Torr to about 100 〇 10 CAC, wherein the CAC is the critical coalescence concentration of the amphiphilic molecule. The organic solvent is removed from the solution, thereby causing the amphiphilic molecules to form particles having a peripheral size of from about 〇 n m to about 10 microns. The granules remained stable in water for more than 6 months. Accordingly, in a first aspect of the invention, a method of forming fluorescent particles 15 is provided. The method comprises providing a solution comprising water, an organic solvent, and an amphiphilic molecule dissolved in an organic solvent; the organic solvent is removed from the solution, thereby forming the amphiphilic molecule to have an outer dimension of from about 10 nm to about 10 microns. 〇 fluorescent particles. The amphipathic knife comprises a plurality of backbone units forming a molecular backbone, and a plurality of side chains grafted to the backbone of the molecule, and each side chain is formed by at least one side chain unit. At least one side chain unit in the molecule is hydrophilic, and at least three backbone units are hydrophobic and fluorescent. The ratio of the weight of the backbone unit and the side chain unit in the molecule to the hydrophobic is from about 1:4 to about 4:1, such as from about 3:7 to about 7:3. The concentration of hydrophilic molecules in the solution is from about 1 to about 1 〇〇〇 cac, such as from about 10 to about 100 CAC, wherein 6 200925244 CAC is the critical coalescence concentration of the two parent molecules. The solution can be prepared by mixing water with the first f solution containing the organic and amphiphilic molecules. The organic solvent can be removed from the solution by evaporation. The solution may have a state of about 12 to about 12 and may be at a temperature of from about 0 to about 80 ° C, such as from about 4 to about 7 〇 5 ❹ 10 15 ❹ 20 oc. According to another aspect of the present invention, there is provided a water-soluble fluorescent particle formed according to the above method. This granule may contain a ligand with a specific affinity for the selected occlusion. The ligand may be selected from the group consisting of avidin, biotin, antibodies, antigens, and DNA, and the target may be selected from the target molecule 'cell, and the organism. According to another aspect of the present invention, there is provided a molecule comprising a plurality of backbone units forming a molecular backbone, and a plurality of side chains grafted with the molecular backbone, and each side chain is formed by at least one side chain unit . The at least one side bond unit in the molecule is hydrophilic, and at least three stem units are hydrophobic and fluorescent. The weight ratio of the hydrophilic backbone unit and the side chain unit to the hydrophobic one in the molecule is from about 1:4 to about 4:1, such as from about 3:7 to about 7.3. According to another aspect of the present invention, there is provided a water-soluble fluorescent particle comprising the molecule described in the preceding paragraph. The particles may comprise a ligand having a specific affinity for the selected target. The ligand may be selected from the group consisting of avidin, biotin, antibodies, antigens, and DNA, and the target may be selected from the group consisting of a target molecule, a cell, and an organism. For the amphiphilic molecules described in the first four paragraphs, the backbone unit may comprise a fluorene unit and the side chain may comprise polyethylene glycol. The backbone unit may comprise an arylene group, a heteroaryl group, an arylene vinylene group, a heteroarylylene vinyl group, an arylene ethylene group or a heteroarylylene group unit, or a derivative thereof. The backbone unit 7 200925244 may comprise alkyl, alkoxy, alkenyl, alkynyl, alkylalkyl, arylalkylaryl, heteroaryl, aryloxy, heteroaryloxy, alkylthioalkyl Amino, dialkylamine, arylamine, diarylamine, aryl ether, heteroaryl ether, aryl sulfide, heteroaryl sulfide, dentate, cyano, nitro, a carbonyl group, a sulfinyl group, a sulfonyl group, or a perfluoroalkyl group, or a unit substituted with an amine group containing a heteroaryl group. The backbone unit may comprise a phenylene group, a porphinyl group, a helix group, a fluorenyl group, a pyridinylene group, a dipyridyl group, an oxazolyl group, an indolocarbazole group, a benzoxazole group. a phenyl group, or an oxadiazolylene unit, or a derivative thereof. At least one backbone unit can be coupled to the vinyl or ethylene group. At least two backbone units may be coupled to each other via a single carbon bond, a propyl group, or an atom selected from the group consisting of ruthenium, s, N, Si' and p. The backbone unit may comprise a flexible base that connects the two hydrophobic and honescent backbone units. The flexible group can be hydrophilic or hydrophobic. The side chain can comprise a side chain unit. The side chain unit may comprise polyethylene glycol, polyethylene diimide, (tetra)amine, polyvinyl ketone, polyacrylic acid, 15 polyethylene glycol, polylysine, or a derivative thereof. At least one side bond may be via a single carbon bond, a single disc bond, an ether group, a thioether group, an amine group, an imido group, a sulphur group, a S group, a sulfur group, a amide group, or a quinone group. Bond with the trunk. Amphiphilic molecules can have chemical formula

至0諸如’ G ’且η係1至2G。1%親性分子可具有化學式 200925244To 0 such as 'G' and η 1 to 2G. 1% paternity molecule can have the chemical formula 200925244

其中,p、q,及η係整數,η係1至20,且p+q係2至200,諸 如,4或10。兩親性分子可具有化學式Wherein p, q, and η are integers, η is 1 to 20, and p + q is 2 to 200, such as 4 or 10. Amphiphilic molecules can have chemical formula

© 5其中,p、q,及η係整數,η係1至20,且p+q係2至200。例 如,於一例示實施例’ η =1,且p = q =1。於另一實施例, n=l,且p = q = 2。兩親性分子可具有化學式© 5 wherein p, q, and η are integers, η is 1 to 20, and p+q is 2 to 200. For example, in an exemplary embodiment, η =1, and p = q =1. In another embodiment, n = 1 and p = q = 2. Amphiphilic molecules can have chemical formula

上述兩親性分子可藉由形成主幹單元之先質,此先質 ® 10 包含疏水性螢光基;使親水性基接枝至此先質,形成經接 枝之先質;及聯接經接枝之先質,因而形成兩親性分子而 形成。此聯接可包含經由偶合反應聯接。此聯接可包含經 由鈐木(Suzuki)偶合反應、格里那(Grignard)偶合反應、史 提勒(Stille)偶合反應、海克(Heck)偶合反應、Sologashira偶 15 合反應、氧化聚合反應、還原聚合反應,或聚縮合反應而 聯接。 本發明之其它方面及特徵熟習此項技藝者藉由下列之 9 200925244 結合附圖之本發明特別實施例說明會變明顯 圖式簡單說明 ~ 於僅藉由舉例而例示說明本發明實施例之圖式中, 第1至15圖係顯示例示本發明實施偏+ / ^ A _ 例之個別特別化合 物之&amp;成路徑之示意化學反應圖; 第16圖係顯示例示本發明實施例之 Α , 眾合物之一般合成 路徑之示意化學反應圖; 第17圖係顯示例示本發明實施例之於主幹具有可挽性 區段之聚合物之一般合成路徑之示意化 10 15 个久應圖; 第i8至2〇圖係顯示不同化合物形成(經測量之顆粒尺 寸之圖; 第21圖係經測量之細胞數之線條圖; 第22圖係自例示本發明實施例之樣品化合物形成之榮 光顆粒之透射式電子顯微術(TEM)圖像;且 第23圖係自例示本發明實施例之另1品化合物形成 之螢光顆粒之透射式電子顯微術(TEM)圖像。 C實施方式;1 詳細說明 已發現當分子内之親水性單元對疏水性單元之重量 2〇比例係約1:4至約4:1(諸如,約3:7至約7:3)時,接枝兩親性 榮光分子可用以形成具足夠平衡之親水性及親疏性之穩定 膠束顆粒。接枝分子具有-份子主幹及與主幹接枝之側 鏈,且該主幹及側鏈之每一者係個別由至少—主幹單元或 側鍵單元形成。如所瞭解,單元於此使用時係指特定^子 200925244 之建構嵌段,例如,若分子係藉由單體之聚合而形成,單 元係單體單元。於本發明之一例示實施例,主幹包含至少 二個疏水性螢光主幹單元,且至少一側量包含至少一親水 性侧鏈單元。次一實施例,主幹可僅包含疏水性主幹單元。 5於一不同實施例,主幹亦可包含一或多個親水性主幹單 疋。為形成螢光顆粒,包含水、有機溶劑,及溶於有機溶 劑之兩親性分子之溶液被提供。溶液内之分子之濃度係約工 至約1000 CAC,諸如,約10至約100 CAC,其中,CAC係 兩親性分子之臨界聚結濃度。有機溶劑自溶液移除,因而 1〇使兩親性分子形成具有約1〇 nm至約1〇微米之外圍尺寸之 膠束顆粒。顆粒可於水中保持穩定多於6個月。 雖不夂任何特別理論所限制,但認為分子内之親水性 及親疏性之足夠平衡係於重量比例係於如上所述範圍内時 達成。可瞭解’親水性及親疏性間之平衡影響顆粒於水中 之穩疋性。虽分子之親水性太強時,顆粒易於水中崩解。 當分子之親疏性太強時,顆粒易於水中聚結或沈殿 。於任 一,況’顆粒於水中係不穩定。當分子内之親水性及疏水 I1 生單元之重量比例係於如上所示範圍内時,顆粒内之各種 區段及水性環境間之交互作用係於動態平衡。因此,顆粒 20於水中或水性環境中維持穩定。顆粒於其尺寸於超過長期 間(諸如,-週或最高達6個月)維持實f上相同時被認為係 穩定。顆粒尺寸係於尺寸之變化對於其間使用顆粒之特定 應用係可允許時被認為係實質上相同。對於不同應用,可 允許·之尺寸變化可能不同。 11 200925244 顆粒於水溶液内之穩定性可使用任何適合技術決定。 例如’溶液可以視覺隨時間檢測其是否保持澄清。若顆粒 沈澱或聚結’沈澱或不澄清之溶液會被觀察到。若溶液保 持澄清’溶_之雛尺寸可使㈣當之絲技術(諸如’,、 5光散射技術)測量或監測。顆幸立尺寸測量 於,例如,ζ·㈣等人’Langmuir,_,第靴= 頁;及W. Brown等人,j. Phys. Chem,1991,第 95冊第 1咖 頁;每一者之内容在此被併入以供參考之用。 於例示之實施例,接枝分子可為共輕聚合物或共執寒 10聚物。主幹係由包含至少3個每一者係疏水性及螢光性之單 元之主幹單元形成。疏水性及螢光性之單元可為重複單 元。側鏈包含親水性側鏈單元。若無其它疏水性或親水性 之區段存在於分子内,分子内之親水性側鏈單元對疏水性 重複單元之重量比例可為約1:4至約4:1。於某些實施例,重 量比例可為約3:7至約7:3。 主幹可包含芳撐基、雜芳撐基、芳撐基乙烯撐基、雜 芳撐基乙締撐基、芳撐基乙撑基,或雜芳樓基乙撑基單元, 或其衍生物。前句或其它相似内容中之“或,,一辭係指列示 項目之每一者本身係可能之另類物,且列示項目之任二戋 20更多之任何組合亦係可能之另類物。主幹單元亦可為笨撐 基、嘍吩撐基、螺旋二苟撐基、茚并苟撐基、吡啶撐基、 二0比咬樓基、咔唑擇基、茚并咔唑樓基、苯并隹唑撐基、 °惡二β坐律基單元,或其衍生物。於本發明之一實施例,主 幹内之重複單元可包含芴單元。於一實施例,主幹單元可 12 200925244 與乙烯撐基或乙撐基聯接。主幹單亦可與一或二個c-c三鍵 聯接。於另一實施例,主幹單元可經由單碳鍵、甲撐基, 或選自O、S、N、Si,及P之之原子彼此聯接。 於不同實施例,主幹單元可包含以有機基取代之單 5元。此有機基可為烷基、烷氧基、烯基、炔基、烷基矽烷 基、芳基矽烷基芳基、雜芳基、芳基氧、雜芳基氧、烷基 — 硫基、烷基胺基、二烷基胺基、芳基胺基、二芳基胺基、 芳基醚、雜芳基醚、芳基硫醚、雜芳基硫醚、鹵素、氰 ® 基、硝基、羰基、亞硫醯基、磺醯基,或全氟烷基,或包 10含雜芳基之胺基。經取代之基可被選擇以改良形成分子於 選擇溶劑内之可溶性。溶劑可為有機溶劑,諸如,四氫呋 喃(THF)、氣仿、二氣曱烷、甲苯等。例如,分子可包含以 己基取代之苟嵌段。 主幹可進一步包含連接主幹内之螢光單元之可撓性 15基。此可撓性基可為親水性或疏水性。例如,可撓性基可 為烧基、經取代或未經取代之烧撑基、稀揮基、炔樓基、 © 醚基、硫醚基、胺基、亞胺基、酯基、硫酯基、醯胺基、 醯亞胺基、矽烷基等。取代基可包含如上列示之基之任一 者、任何經取代或未經取代之芳基或雜芳基、任何雜原子, 20 或其等之任何組合。 側鏈可包含側鍵單元’其因而包含親水性單元。於側 鍵或於主幹之親水性早元可包含聚乙二醇(peg)、聚乙二亞 胺、聚醯胺、聚乙烯基吡咯烷酮、聚丙烯酸、聚乙烯基醇, 或聚賴氨酸,或其衍生物。侧鏈内之親水性單元可經由單 13 200925244 或w鍵、喊基、硫醚基、胺基、亞胺基、碎烧基、醋基、 瓜酉0基、醯胺基,或醯亞胺基與主幹鍵結。親水性側鏈可 於主幹之端部或中間與主幹之任何位置聯接。 若提供特定分子之化學結構或化學式,分子内之親水 5性及疏水性單元(區段)可由熟習此項技藝者輕易鑑別。然 後刀子内之此二型式之單元(區段)之重量比例可以個別單 、 疋(區段)内存在之元素之原子量為基礎而計算。分子内之所 有親水性區段之總重量及所有疏水性區段之總重量可被個 別计算,且用以計算其比例。另外,對於由重複單體單元 ❹ 10形成之聚合物或寡聚物,聚合物之每一單體單元内之二種 區段之重量比例可被計算及用以決定整個聚合物之重量比 例。重量比例亦可以熟習此項技藝者所知之另一適合方式 決定。 於一實施例,接枝分子可如下般形成。主幹單元之先 15質係自可獲得之商業來源(諸如,Sigma-Aldrich™、The amphiphilic molecule may be formed by forming a precursor of a stem unit, the precursor® 10 comprising a hydrophobic fluorescent group; grafting a hydrophilic group to the precursor to form a grafted precursor; and grafting grafting It is formed by the formation of amphiphilic molecules. This coupling can include coupling via a coupling reaction. This linkage may include a Suzuki coupling reaction, a Grignard coupling reaction, a Stille coupling reaction, a Heck coupling reaction, a Sologashira coupling reaction, an oxidative polymerization reaction, and a reduction. The polymerization reaction, or the polycondensation reaction, is coupled. Other aspects and features of the present invention will become apparent to those skilled in the <RTIgt; </RTI> <RTIgt; </ RTI> <RTIgt; In the formula, Figures 1 to 15 show schematic chemical reaction diagrams illustrating the &amp; path of individual specific compounds of the partial + / ^ A _ example of the present invention; Figure 16 is a diagram showing the exemplification of the embodiment of the present invention. A schematic chemical reaction diagram of a general synthetic route of a compound; Figure 17 is a schematic representation of a general synthetic route illustrating a polymer of a backbone having a levisable segment of the embodiment of the invention; Figure 2 shows the formation of different compounds (measured particle size; Figure 21 is a line drawing of the measured cell number; Figure 22 is a transmission of the glare particle formed by the sample compound of the embodiment of the invention. Electron microscopy (TEM) image; and Fig. 23 is a transmission electron microscopy (TEM) image of fluorescent particles formed by another compound of the present invention. C embodiment; DETAILED DESCRIPTION It has been found that when the ratio of the weight of the hydrophilic unit to the hydrophobic unit in the molecule is from about 1:4 to about 4:1 (such as from about 3:7 to about 7:3), the graft amphiphilicity The glory molecule can be used to form a stable micelle particle having a sufficiently balanced hydrophilicity and affinity. The graft molecule has a --meridend backbone and a side chain grafted with the stem, and each of the stem and the side chain is individually at least - a stem unit or a side bond unit is formed. As understood, a unit as used herein refers to a building block of a particular moiety 200925244, for example, if a molecule is formed by polymerization of a monomer, the unit is a monomer unit. In an exemplary embodiment of the invention, the backbone comprises at least two hydrophobic fluorescent backbone units, and at least one side comprises at least one hydrophilic side chain unit. In the next embodiment, the backbone may comprise only hydrophobic backbone units. In a different embodiment, the backbone may also comprise one or more hydrophilic backbone units. To form the fluorescent particles, a solution comprising water, an organic solvent, and an amphiphilic molecule dissolved in an organic solvent is provided. The concentration is about Up to about 1000 CAC, such as from about 10 to about 100 CAC, wherein the CAC is a critical coalescence concentration of the amphiphilic molecule. The organic solvent is removed from the solution, thereby causing the amphiphilic molecule to form with about 1 〇 nm to Micelle particles of about 1 micron in size. The particles can remain stable in water for more than 6 months. Although not limited by any particular theory, it is considered that the balance of hydrophilicity and affinity in the molecule is based on the weight ratio. It is achieved when it is within the above range. It can be understood that the balance between hydrophilicity and affinity affects the stability of the particles in water. Although the hydrophilicity of the molecule is too strong, the particles are easily disintegrated in water. When it is too strong, the particles tend to coalesce or sink in the water. In either case, the particles are unstable in water. When the hydrophilicity of the molecule and the weight ratio of the hydrophobic I1 unit are within the ranges indicated above, the interaction between the various segments within the particle and the aqueous environment is in dynamic equilibrium. Therefore, the particles 20 remain stable in water or in an aqueous environment. The particles are considered to be stable when their dimensions are the same over a long period of time (such as - weeks or up to 6 months). The change in particle size from size is considered to be substantially the same for a particular application in which the particles are used. Dimensional variations may be allowed for different applications. 11 200925244 The stability of the granules in aqueous solution can be determined using any suitable technique. For example, the solution can be visually detected over time to see if it remains clear. If the particles are precipitated or coalesced, a precipitate or a solution that is not clear will be observed. If the solution is kept clear, the size of the solution can be measured or monitored by the silk technology (such as ', 5 light scattering technology). The size of the glory is measured, for example, ζ·(4) et al. 'Langmuir, _, the first boots = page; and W. Brown et al, j. Phys. Chem, 1991, page 95, the first coffee page; each The content is hereby incorporated by reference. In the illustrated embodiment, the grafting molecule can be a co-light polymer or a co-pressing cold 10 polymer. The backbone is formed from a backbone unit comprising at least three hydrophobic and fluorescing units. The unit of hydrophobicity and fluorescing can be a repeating unit. The side chain contains hydrophilic side chain units. If no other hydrophobic or hydrophilic segments are present in the molecule, the weight ratio of hydrophilic side chain units to hydrophobic repeat units in the molecule can range from about 1:4 to about 4:1. In certain embodiments, the weight ratio can range from about 3:7 to about 7:3. The backbone may comprise an arylene group, a heteroaryl group, an arylene vinylene group, a heteroarylylene group, an arylene group, or a heteroaryl group ethylene unit, or a derivative thereof. In the preceding sentence or other similar content, "or" means that each of the items listed is a possible alternative, and any combination of any two of the items listed in the item is also a possible alternative. The backbone unit may also be a stupid base, a porphinyl group, a helical diterpene group, an anthracene fluorene group, a pyridyl group, a bismuth base, a carbazole group, an indolocarbazole group, a benzoxazole group, a sulphur beta-study unit, or a derivative thereof. In one embodiment of the invention, the repeating unit in the backbone may comprise a fluorene unit. In one embodiment, the backbone unit may be 12 200925244 The vinyl group or the ethylene group is bonded. The trunk sheet may also be bonded to one or two cc triple bonds. In another embodiment, the stem unit may be via a single carbon bond, a methylene group, or selected from O, S, N, The atoms of Si and P are coupled to each other. In various embodiments, the backbone unit may comprise a single 5-membered with an organic group. The organic group may be an alkyl group, an alkoxy group, an alkenyl group, an alkynyl group, an alkylalkyl group. , arylalkylaryl, heteroaryl, aryloxy, heteroaryloxy, alkyl-thio, alkylamino, Alkylamino, arylamine, diarylamine, aryl ether, heteroaryl ether, aryl sulfide, heteroaryl sulfide, halogen, cyanide, nitro, carbonyl, sulfoxide a sulfonyl group, or a perfluoroalkyl group, or an amine group containing a heteroaryl group. The substituted group may be selected to improve the solubility of the forming molecule in a selective solvent. The solvent may be an organic solvent such as tetrahydrofuran. (THF), gas, dioxane, toluene, etc. For example, the molecule may comprise a hydrazine block substituted with a hexyl group. The backbone may further comprise a flexible 15 group linking the fluorescent units in the backbone. The group may be hydrophilic or hydrophobic. For example, the flexible group may be an alkyl group, a substituted or unsubstituted alkyl group, a dilute group, an alkyne group, an ether group, a thioether group, an amine group, An imido group, an ester group, a thioester group, a decylamino group, a guanidino group, a decyl group, etc. The substituent may contain any of the groups listed above, any substituted or unsubstituted aryl or hetero An aryl group, any hetero atom, any combination of 20 or the like. The side chain may comprise a side bond unit which thus comprises a hydrophilic The hydrophilic early element of the side bond or the backbone may comprise polyethylene glycol (peg), polyethylenediamine, polyamine, polyvinylpyrrolidone, polyacrylic acid, polyvinyl alcohol, or polylysine. Acid, or a derivative thereof. The hydrophilic unit in the side chain may be via a single 13 200925244 or a w bond, a thiol group, a thioether group, an amine group, an imido group, a calcined group, a vine group, a quinone group, a hydrazine group, a hydrazine group The amine group or the quinone imine group is bonded to the backbone. The hydrophilic side chain can be bonded to any position of the stem at the end or in the middle of the stem. If the chemical structure or chemical formula of a specific molecule is provided, the hydrophilicity and hydrophobicity within the molecule are provided. The sex unit (segment) can be easily identified by those skilled in the art. Then, the weight ratio of the unit (segment) of the two types in the knife can be calculated based on the atomic weight of the element existing in the individual block and the segment (segment). The total weight of all hydrophilic segments within the molecule and the total weight of all hydrophobic segments can be calculated individually and used to calculate the ratio. Alternatively, for a polymer or oligomer formed from repeating monomer units ❹ 10, the weight ratio of the two segments in each monomer unit of the polymer can be calculated and used to determine the weight ratio of the entire polymer. The weight ratio can also be determined by another suitable method known to those skilled in the art. In one embodiment, the grafted molecules can be formed as follows. The first of the main units is from a commercially available source (such as Sigma-AldrichTM,

Fluka™、Merck™、TCL™、Alfa Aesar,製備或獲得。先 、 質可使用熟習此項技藝者所知之任何適合技術製備。至少 〇 一些先質係包含疏水性螢光基。包含親水性侧鏈基之側鏈 係與個別先質接枝,形成經接枝之先質。經接枝之先質可 2〇為相同或相異之分子。然後,經接枝之先質聯接形成最終 之接枝分子。側键對先質之比例被選擇以使親水性區段對 疏水性區段之重量比例係約1:4至約4:1,諸如,約3:7至約 7:3。每一經接枝之先質可為單體、募聚物,或聚合物。接 枝分子内之不同之經接枝之先質之化學計量比例可改變, 14 200925244 且可依所欲之主幹尺寸、分子量、可溶性、生物利用性、 生物相容性、光學性質,或其它相關特性而選擇。經接枝 之先質可經由偶合反應聯接在一起。偶合反應可為铃木偶 合反應、格里那偶合反應,或史提勒偶合反應。經接枝之 5先質亦可經由氧化聚合反應、還原聚合反應、聚縮合反應、 海克反應、Sologashira反應等聯接形成經接枝之分子。如 熟習此項技藝者能瞭解,經接枝之先質可直接聯接,或藉 由其它主幹單元間接聯接。聯接經接枝之先質之聯接主幹 〇 單可不具有與其附接之側鏈’或具有一或多個與其附接之 10 側鏈。例如,聯接主幹單元可為可撓性基。 於一不同實施例,接枝分子可使用其它程序形成。例 如’聚合物主幹可先被製備,然後,側鏈於後聚合反應接 枝至主幹。於一範例,具0H端基或胺基之PEG可被接枝至 . 包含烷基溴基、酸氣化物基,或酐基之聚合物主幹。於另 15 一範例,具酸氯化物基或酐基之側鏈可被接枝至包含〇H基 或胺基之主幹。例示之後聚合反應技術係揭示於Cuihua ❺ Xue 等人,“Facile,versatile prepolymerization and postpolymerization functionalization approaches for well-defined fluorescent conjugated fluorene-based 20 glycopolymers”,Macromolecules, 2006,第 39冊,編號 17, 5747-5752 頁;Κ· Buga等人,“Postpolymerization grafting of aniline tetramer on polythiophene chain: Structural organization of the product and its electrochemical and spectroelectrochemical properties&gt;,, Chemistry Of Materials, 15 200925244 2005,第 17 冊,編號 23,5754-5762 頁;K. Buga 等人, “Poly(alkylthiophene) with pendant dianiline groups via postpolymerization functionalization: preparation, spectroscopic, and spectroelectrochemical characterization”, 5 Macromolecules,2004,第 37冊,編號3,769-777 頁;及 J.S.FlukaTM, MerckTM, TCLTM, Alfa Aesar, prepared or obtained. Preferably, the quality can be prepared using any suitable technique known to those skilled in the art. At least 〇 Some precursors contain hydrophobic fluorescent groups. The side chain comprising a hydrophilic side chain group is grafted with the individual precursors to form a grafted precursor. The grafted precursor can be the same or a different molecule. The grafted precursor is then joined to form the final grafted molecule. The ratio of side bonds to precursors is selected such that the weight ratio of hydrophilic segments to hydrophobic segments is from about 1:4 to about 4:1, such as from about 3:7 to about 7:3. Each grafted precursor can be a monomer, a polymer, or a polymer. The stoichiometric ratio of the different grafted precursors in the grafted molecule can be varied, 14 200925244 and depending on the desired stem size, molecular weight, solubility, bioavailability, biocompatibility, optical properties, or other correlation Choose from features. The grafted precursors can be coupled together via a coupling reaction. The coupling reaction can be a Suzuki coupling reaction, a Grignard coupling reaction, or a Stiller coupling reaction. The grafted 5 precursor may also be linked to form a grafted molecule via an oxidative polymerization reaction, a reduction polymerization reaction, a polycondensation reaction, a Heck reaction, a Sologashira reaction or the like. As will be appreciated by those skilled in the art, grafted precursors can be directly coupled or indirectly coupled by other backbone units. The coupled backbone of the grafted precursor may have no side chains attached thereto or one or more side chains attached thereto. For example, the coupling stem unit can be a flexible base. In a different embodiment, the grafted molecules can be formed using other procedures. For example, the 'polymer backbone can be prepared first, and then the side chains are grafted to the backbone in a post polymerization process. In one example, a PEG having a 0H end group or an amine group can be grafted to a polymer backbone comprising an alkyl bromide group, an acid vapor group, or an anhydride group. In another example, a side chain having an acid chloride group or an anhydride group may be grafted to a backbone comprising a hydrazine H group or an amine group. The post-polymerization technique is illustrated in Cuihua ❺ Xue et al., "Facile, versatile prepolymerization and postpolymerization functionalization approaches for well-defined fluorescent conjugated fluorene-based 20 glycopolymers", Macromolecules, 2006, Vol. 39, No. 17, 5747-5752 Page; Κ· Buga et al., "Postpolymerization grafting of aniline tetramer on polythiophene chain: Structural organization of the product and its electrochemical and spectroelectrochemical properties&gt;,, Chemistry Of Materials, 15 200925244 2005, Vol. 17, No. 23,5754-5762 Page; K. Buga et al., "Poly (alkylthiophene) with pendant dianiline groups via postpolymerization functionalization: preparation, spectroscopic, and spectroelectrochemical characterization", 5 Macromolecules, 2004, Vol. 37, No. 3, 769-777; and JS

Liu 及 R.D. McCullough,“End group modification of regioregular polythiophene through postpolymerization functionalization”,Macromolecules,2002,第 35冊,編號27, 9882-9889頁,每一者之内容在此被併入以供參考之用。 10 本發明之某些例示實施例係有關於自如上所述之接枝 分子形成之水溶性螢光顆粒。顆粒可具有1〇 nm至10微米之 外圍尺寸。當顆粒係球形時,外圍尺寸係顆粒直徑。當顆 粒具有不規則形狀或未均一尺寸時,外圍尺寸係指顆粒之 有效或平均直徑。非球形顆粒之有效直徑係具有與非球形 15直徑者相同體積之球形顆粒之直徑。顆粒之尺寸可使用任 何適合技術測量’包含光學或電子成像技術。例如,顆粒 之尺寸可使用光散射技術測量。 0 顆粒可包含對選擇之標靶具特定親和力之配位體。例 如,此配位體可為親和素、生物素、抗體、抗原,或DNA, 20且標靶可為分子、細胞,或有機體。 於一例不實施例,顆粒可如下般形成。 含有溶於有機軸内之純分子之第 一溶液被獲得。 有機溶劑可為THF、氣仿、二氣甲炫、甲苯等。第一溶液 T為自接枝;^子之形成方法之產物溶液。依特定情況而 16 200925244 5 ❹ 10 15 ❹ 20 定’產物溶液可接受進一步之選擇或必要之處理。第一溶 液亦可藉由使接枝分子溶於有機溶劑而個別製備。第一溶 液與水混合,因而形成第二溶液。為形成第二溶液,水或 水溶液可添加至第一溶液,或第一溶液可添加至水或水溶 液。水溶液包含水,且亦可包含PH緩衝溶液。第二溶液内 之接枝分子之濃度需被控制。假設特定之接枝分子於第二 溶液内具有臨界聚結濃度,CAC,第二溶液内之接枝分子 之濃度於一實施例中需為約1至約1000 CAC,且於另一實 施例係約10至約100 CAC。特定溶液内之特定接枝分子之 CAC可藉由於增加接枝分子濃度時監測自溶液發射之光線 強度而決定。當溶液内之接枝分子之濃度係於CAC值或接 近時,發光強度展現急劇地增加。CAC可依據,例如,K.Liu and R. D. McCullough, "End group modification of regioregular polythiophene through postpolymerization functionalization", Macromolecules, 2002, vol. 35, No. 27, pp. 9882-9889, the contents of each of which are incorporated herein by reference. 10 Certain exemplary embodiments of the invention relate to water soluble fluorescent particles formed from grafting molecules as described above. The particles may have an outer dimension of from 1 〇 nm to 10 μm. When the particles are spherical, the peripheral size is the particle diameter. When the particles have an irregular shape or a non-uniform size, the peripheral size refers to the effective or average diameter of the particles. The effective diameter of the non-spherical particles is the diameter of the spherical particles of the same volume as those of the non-spherical 15 diameter. The size of the particles can be measured using any suitable technique&apos; including optical or electronic imaging techniques. For example, the size of the particles can be measured using light scattering techniques. 0 Particles may contain ligands with a specific affinity for the selected target. For example, the ligand can be avidin, biotin, antibody, antigen, or DNA, 20 and the target can be a molecule, a cell, or an organism. In one example, the particles can be formed as follows. A first solution containing a pure molecule dissolved in an organic shaft is obtained. The organic solvent may be THF, gas, dioxane, toluene or the like. The first solution T is a product solution of a self-grafting method. Depending on the circumstances 16 200925244 5 ❹ 10 15 ❹ 20 The 'product solution' can be further selected or treated as necessary. The first solution can also be prepared individually by dissolving the grafting molecule in an organic solvent. The first solution is mixed with water to form a second solution. To form the second solution, water or an aqueous solution may be added to the first solution, or the first solution may be added to water or an aqueous solution. The aqueous solution contains water and may also contain a pH buffer solution. The concentration of the grafted molecules in the second solution needs to be controlled. Assuming that the specific grafting molecule has a critical coalescence concentration in the second solution, the concentration of the grafted molecules in the second solution in the CAC needs to be from about 1 to about 1000 CAC in one embodiment, and in another embodiment About 10 to about 100 CAC. The CAC of a particular graft molecule in a particular solution can be determined by monitoring the intensity of the light emitted from the solution as the concentration of the grafted molecule is increased. When the concentration of the grafted molecules in the solution is at or near the CAC value, the luminescence intensity exhibits a sharp increase. CAC can be based on, for example, K.

Holmberg 等人 ’ Handbook of applied surface and colloid chemistry,2002,第2冊,第13章所揭示之人列示方法測 量’其内容在此被併入以供參考之用。 有機溶劑其次自第二溶液移除,因而使接枝分子,諸 如,經由自行組合而形成顆粒◎有機溶劑可藉由蒸發或另 外技術移除。例如’旋轉式蒸發技術可被使用。有機溶劑 之蒸發可藉由使第二溶液曝置於真空,藉由加熱,或藉由 二者而促進。於某些實施例’至少9〇%之有機溶劑需被移 除。自行組合之方法係藉由接枝分子及水中之不同區段間 之親水性及疏水性交互作用而趨動。一般,疏水性區段與 水分子彼此排斥,而親水性區段與水分子彼此吸引。為促 進自行組合方法,第二溶液可具有約2至約12ipH,其係依 17 200925244 應用而定。於蒸發及顆粒形成期間,第二溶液可被維持於 約〇 X至約80。(:之溫度,諸如,約4 〇c至約7〇 %。 5 形成溶液及其内形成之顆粒可接受任何適合之後形成 處理,諸如,擠塑、純化、乾燥等,其係依應用而定。 於不同實施例’顆粒可使用不同程序形成。例如,顆 粒可藉由使兩親純段絲聽於水及有機_之混合物 内形成混合物溶液而形成,且有機溶劑可於不同方法自混 10 合物溶液萃取。於-例㈣法(透析方法),混合物溶液被轉 移至透析管内’然、後,浸於水浴内。由於濃度差,有機溶 劑會自管擴散於水浴内。水谷可隨時間(諸如,每二(2)小時) 更新。更新方法可重複至有機溶劑實f上自管内之溶液移 ❹ 15 除為止。典型上,此方法可費時二至三天完成。管内之剩 餘溶液會含有形成之顆粒。透析程序即時於有機溶劑不是 極具揮發性時亦可被使用。另外之溶劑移除技術係音波注 射方法,其可於有機溶劑係揮發性時使用,諸如,或 丙酮。於此技術,混合溶液可於音波處理下緩慢注射至(純 水積積内。形成之溶液可以音波處理—段時間,諸如,約 10分鐘。經音波處理之溶液於室溫攪拌,例如,2天以藉由 蒸發移除有機溶劑。Holmberg et al. 'Handbook of applied surface and colloid chemistry, 2002, Vol. 2, Chapter 13 discloses a method of measuring the measurement', the contents of which are hereby incorporated by reference. The organic solvent is secondarily removed from the second solution, thereby allowing the grafted molecules, for example, to form particles by self-assembly. The organic solvent can be removed by evaporation or another technique. For example, a rotary evaporation technique can be used. Evaporation of the organic solvent can be promoted by exposing the second solution to a vacuum, by heating, or by both. In certain embodiments, at least 9% of the organic solvent needs to be removed. The self-assembling method is motivated by the interaction of hydrophilic and hydrophobic interactions between the grafted molecules and different segments in the water. Typically, the hydrophobic segments and the water molecules repel each other, while the hydrophilic segments and water molecules attract each other. To facilitate the self-assembly method, the second solution can have from about 2 to about 12 ipH, depending on the application of 17 200925244. The second solution can be maintained at about 〇 X to about 80 during evaporation and particle formation. (The temperature, such as, from about 4 〇c to about 7〇%. 5 The forming solution and the particles formed therein may be subjected to any suitable post-forming treatment, such as extrusion, purification, drying, etc., depending on the application. In different embodiments, the granules can be formed using different procedures. For example, the granules can be formed by forming an amphiphilic pure segment of silk into a mixture solution of water and organic, and the organic solvent can be self-mixed in different ways. Extraction of the solution solution. In the method of (4) (dialysis method), the mixture solution is transferred to the dialysis tube, and then immersed in a water bath. Due to the difference in concentration, the organic solvent will diffuse from the tube into the water bath. (eg, every two (2) hours) update. The update method can be repeated until the organic solvent is removed from the solution in the tube. Typically, this method can take two to three days to complete. The remaining solution in the tube will Contains formed particles. The dialysis procedure can be used immediately when the organic solvent is not very volatile. Another solvent removal technique is the sonic injection method, which can be used when the organic solvent is volatile. For example, or acetone. In this technique, the mixed solution can be slowly injected under the sonication treatment (in the pure water accumulation. The formed solution can be sonicated for a period of time, such as about 10 minutes. The sonicated solution is Stir at room temperature, for example, for 2 days to remove the organic solvent by evaporation.

20 預期於上述例示方法製備之形成螢光顆粒係可溶於 水丄且於水性環境(諸如,水)中,於㈣較長時間消如, 最高達6個月)會展現穩定之榮光釋放(例如,見如下之實施 例I3)。比較中,當奈米尺寸之顆粒係使用具有相似址份: 顆粒内之親水性區段對疏水性區段之重量比例係於w至 18 200925244 4:1之範圍外之兩親性分子形成時,顆粒於水中可能不穩 定,且其諸如螢光探測之性能被預期於相對較短時間(諸 如,1天至一週内)會惡化。例如,兩親性接枝聚合物2,7_ 一溴-9,9(6 -聚乙二醇-己基)芴及2_溴_9,9(6,_聚乙二醇_己基) 5苟已被發現於水中係不穩定。此二化合物内之親水性區段 與疏水性區段之重量比例係約10:1。相反地,測試結果顯 示當重量比例係約1:4至約4:1之範圍内,且第二溶液内之接 枝分子之濃度係約1至約1000 CAC(諸如,約10至約100 CAC)時,測試樣品接枝分子形成被觀察於水中係於延長時 1〇期(諸如,多於6個月)呈穩定之螢光顆粒。 於一特別實施例,接枝分子之主幹包含寡芴或聚芴, 且側鏈包含PEC^PEG單元可具有任何適合之尺寸或重量。 接枝分子之經接枝之先質可經由鈴木偶合反應聯接。 Μ刀子内之PEG對寡或聚苟之重量比例係約1:4至4:1,或約3:7 至約7.3。於第一溶液,有機溶劑可為曱苯或二氣甲烷。第 〇 货’合液可於混合溶液被攪拌時以滴液方式添加至水。有機 劑可藉由蒸發移除。形成之顆粒可具有數奈米至數微米 卜圍尺寸。第一溶液及分散於水中之形成顆粒會展現強 I之榮光發射。螢光可使用螢光光譜計或共聚焦光譜計測 20量。 藉由此等顆粒展現之強烈螢光可用於成像或檢測之應 用,钱· ,於生物應用。例如,顆粒可附至特定配位體。 位體可為核苷酸、單股DNA、雙股dna、單股RNA、雙 ΗΠ- 15 τντ a 、肽、蛋白質、荷爾蒙、抗體、受體、抗原、抗原 19 200925244 決定基、核酸結合蛋白、分子、酶基材或其類似物、親和 素、鏈黴親和素、生物素、單醣、多醣等。具特定配位體 之顆粒可用以標定特定細胞或有機體。當顆粒尺寸一般於 奈米範圍時,其可藉由細胞或有機體輕易吸收。顆粒亦可 5被製備以使其與選定之環境(諸如,圍繞細胞)相容。例如, 顆粒之組份可被選擇以使顆粒之存在不會發生非所欲之作 用,諸如,對細胞具毒性。 實施例 實施例1(化合物1之合成) ® 10 化合物1係2,7_二溴~(9,9-二己基)芴,其係依據第1圖所 示之反應製備。2,7-二溴芴(9.72克,30毫莫耳,自 Sigma-Aldrich獲得)添加至於8〇〇c之水性氫氧化鈉(54.3毫 升,50%)、四丁基銨溴化物(1 82克,5.63毫莫耳),及1_溴 己烧(25.36毫升’ 180毫莫耳)之混合物。於授拌5小時後’ - 15 混合物冷卻至室溫。混合物與二氣曱烷混合以萃取反應產 物。有機層依序以水、含水之HC1、水,及鹽水清洗。經清 0 洗之層使用無水MgS04乾燥。剩餘溶劑及過量之1-溴己烷 被移除。殘質使用矽石凝膠管柱色譜分析術且以己烷作為 洗提液而純化。經純化之產物含有白色固體,其重量係 20 14.55克,相對應於98.6重量%之產率。白色固體之經測量 之光譜係:NMR (CDC13, 400MHz) δ[ρρπι]: 7.513 (m,6H), 1.908 (m, 4H), 1.119 (m, 12H), 0.782 (t, 6H), 0.583 (m, 4H),確認產物含有化合物1 ’ 2,7-二漠-(9,9-二己基)¾。 實施例2(化合物2之合成) 20 200925244 化合物2係2,7-雙(4,4,5,5-四甲基_U,2_二噁硼烷_2_ 基)9,9-二己基芴,其係依據第2圖所示之反應使用化合物i 製備。 2.46克(5毫莫耳)之化合物1添加至THF(5〇毫升)形成溶 5 液。溶液被冷卻至-78。(:。15毫升(18毫莫耳)之正丁基鋰 (1.2M ’於己烧’自Aldrich™獲得)添加至溶液形成混合物。 混合物授拌1小時,且溶液溫度維持於_78〇c。2_異丙氧基 -4,4,5,5-四曱基-1,3,2-二噁硼烷(2.7毫升,12.98毫莫耳)其次 被快速添加至混合物。形成之混合物加溫至室溫,並且擾 10拌隔夜。混合物倒至水内。混合物内之反應產物使用醚萃 取。萃取方法重複3次。經萃取之有機層被混合,且以鹽水 清洗,且於無水硫酸鎂乾燥。剩餘之溶劑藉由旋轉式蒸發 移除。殘質藉由矽石管柱色譜分析術(乙酸乙酯:己烷=1:15) 純化。經純化之產物含有1.823克之白色固體(產生62重量% 15之產率)。白色固體之經測量之光譜係1H NMR (CDC13, 400MHz) 8[ppm]: 7.793 (d, 2H, J=7.6Hz), 7.742 (s, 2H), 7.725 (d, 2H, J=7.6Hz), 1.995 (m, 4H), 1.386 (s, 24H), 1.064 (m, 12H),0.740 (t, 6H), 0.546 (m,4H),確認產物係化合物 2 ’ 2,7-雙(4,4,5,5-四甲基-1,3,2-二噁硼烷_2-基)9,9-二己基 20 芴。 實施例3(化合物3之合成) 化合物3係2-溴-(9,9-二己基)芴,其係依據第3圖所示之 反應合成。2-溴芴(12.25克,50毫莫耳)添加至於8(TC之含 水之氫氧化鈉(91毫升,50%)、四丁基銨溴化物(3.03克,9.38 21 200925244 毫莫耳)及1-溴己烷(42.3毫升,300毫莫耳)之混合物。攪 拌4小時後,混合物冷卻至室溫。以二氣甲烷萃取後,混合 之有機層依序以水、含水之HC1、水,及鹽水清洗,然後, 於無水MgSCU乾燥。自經乾燥之層移除剩餘溶劑及過量之 5 1-溴己烷後,殘質藉由矽石凝膠管柱色譜分析術使用己烷 作為洗提液而純化。形成之產物含有20.〇3克(97重量%產率) 之淡黃色液體產物,且經測量之光譜係4 NMR (CDC13, 400MHz) 5[ppm]: 7.681 (m, 1H), 7.57 (d, J=7.7Hz, 1H), 7.45 (m, 2H), 7.35 (m, 3H), 1.95 (m,4H), 1.09 (m, 12H), 0.79 (t, 10 】=7.1沿,611),0.62(111,411)。產物係化合物3,2-溴一(9,9-二 己基)芴。 實施例4(化合物4之合成) 化合物4係2-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)-9,9-二己基芴,其係依據第4圖所示之反應使用化合物3而製 15備。62克(15毫莫耳)之化合物3與100毫升之無水THF混合 形成溶液。22.5毫升之n-BuLi(27毫莫耳)添加至此溶液,其 係於-78°C。溶液於添加2_異丙氧基_4 4 5 5_四甲基H2-二噁硼烷(3.9毫升,18.75毫莫耳)前攪拌1小時。形成之混合 物授拌隔夜。然後,添加水以使進一步之反應驟總。混合 20物中之反應產物以二氣甲烷(100毫升)萃取3次。萃取之有機 層以鹽水清洗’於無水MgS04乾燥,然後,於真空濃縮。 經濃縮之層接受管柱色譜分析術(矽石凝膠,乙酸乙酯:己烧 =1: 20),產生重5.83克(84.5重量%產率)之產物。產物之經 測量之光譜係 1H NMR (CDC13, 400MHz) δ[ρριη]: 7.812 (m, 200925244 1H), 7.747 (m, 3H), 7.322 (m, 3H), 7.322 (m, 3H), 1.990 (m, 4H), 1.39 (s, 12H), 1.023 (m, 12H), 0.752 (m, 6H), 0.597 (m, 4H),確認產物係化合物4, 2-(4,4,5,5-四甲基-1,3,2-二噁硼烷 -2-基)-9,9-二己基芴。 5 實施例5(化合物5之合成) 化合物5係2,7-二溴-9,9-雙(6,-溴己基)¾,其係依據第5 圖所示之反應製備。2,7-二溴芴(0.972克,3毫莫耳)添加至 於75°C之含水氫氧化鉀(60毫升,50%)、四丁基銨溴化物 Ο (0.198克,0.6毫莫耳)’及1,6-二己院(7.32克,30毫莫耳)之 10 混合物。於攪拌15分鐘後,混合物冷卻至室溫。以二氯甲 烷萃取後,混合之有機層依序以水、含水之HC1、水,及鹽 水清洗,然後,於無水MgS04乾燥。移除剩餘之溶劑及過 量之1,6-二溴己烷後’殘質藉由矽石凝膠管柱色譜分析術 使用己烷:氣仿(v/v: 9:1)作為洗提液而純化。形成之產物含 15 有1·47克(75重量%產率)之白色固體,且測量之光譜係1Η NMR (CDC13, 400MHz) δ (ppm): 7.433-7.535 (m, 6H), 3.294 ❹ (t, 4H), 1.923 (m, 4H), 1.652-1.687 (m, 4H), 1.203 (m, 4H), 1.083 (m, 4H),0.587 (m, 4H),確認產物係化合物5,2,7-二 溴-9,9-雙(6,-溴己基)苟。 20 實施例6(化合物6之合成) 化合物6係2,7-二溴-9,9(6’-聚乙二醇-己基)芴,其係依 據第6圖所示之反應使用化合物5而製備。氫化鈉(0.9克,40 毫莫耳)及無水THF(30毫升)於氬氣氛圍下置於三頸之150 毫升燒瓶内。然後,於THF(50毫升)内之PEG(8克,4毫莫耳) 23 200925244 於至/BZL以滴液方式添加。如第6圖所示,使用之peg之分子 量係2000道爾頓,以PEG2000或PEG2_表示。但是,需瞭 解PEG2000係用於測試目的,且於本發明之不同實施例, PEG之重量可改變。 5 形成之混合物攪拌4小時。其次,0.65克(1毫莫耳)之化 合物5添加至燒瓶。燒瓶内之混合物於室溫攪拌約1週。其 - 次,以滴液方式添加水以終結進一步之反應。混合物内之 有機溶劑被蒸發掉,且殘質溶於20毫升之二氣甲烷及4毫升 之曱醇。溶液與500毫升之醚混合形成沈澱物。沈澱物藉由 ❹ 10離心掉溶劑而收集。沈澱物藉由重複上述方法3次而進一步 純化,然後,於真空乾燥。形成之產物係化合物6。 實施例7(化合物7之合成) 化合物7係2-溴-9,9-雙(6,-溴己基)芴,其係依據第7圖所 不之反應製備。2-溴芴(4.9克,20毫莫耳)添加至於75°c之 15含水氫氧化鉀(400毫升,50%)、四丁基敍溴化物(1.32克,4 毫莫耳)’及1,6-二溴己烧(48.8克,200毫莫耳)之混合物。 攪拌15分鐘後,混合物冷卻至室溫。以二氣甲烷萃取後, ◎ 混合之有機層依序以水、含水之Ηα、水,及鹽水清洗,然 後,於無水MgS〇4乾燥。移除剩餘之溶劑及過量之丨,6_二 漠己烧後’殘質藉由石夕石凝膠管柱色譜分析術使用己烧/氣 仿(v:v = 9:1)作為洗提液而純化。產物係淡黃色液體,重8 6 克(75重量%產率),測量之光譜係iH NMR (CDCl3, 4〇〇MHz) δ (ppm): 7.669 (m, 1H), 7.548 (m, 1H), 7.453 (m, 2H), 7.322 (m, 3H), 3.280 (t, 4H), 1.943 (m, 4H), 1.657 (m, 4H), 1.193 24 200925244 (m,4Η),1·073 (m,4Η)’ 0.604 (m, 4Η),確認產物係化合物 7,2-漠-9,9-雙(6’-漠己基)苟。 實施例8(化合物8之合成) 5 φ 10 15 ❹ 20 化合物8係2_溴_9,9(6’-聚乙二醇-己基)苟,其係依據第8 圖所示之反應使用化合物7而合成。 氫化鈉(0.96克’ 40毫莫耳)及無水THF(3〇毫升)於氬氣 氛圍下置於三頸之150毫升燒瓶内。於thf(50毫升)内之 PEG(8克’ 4毫莫耳)於室室以滴液方式添加。混合物擾摔4 小時。其次’ 0.57克(1毫莫耳)之化合物7添加至混合物。混 合物於室溫進一步攪拌約一週。然後,水以滴液方式添加 至燒瓶以終結進一步之反應。使溶液蒸發而移除THF。剩 餘之混合物溶於20毫升之二氣甲烷及4毫升之甲醇,然後, 與500毫升之醚混合形成沈澱物。混合物内之溶劑藉由離心 作用移除。上述沈澱方法重複3次。形成之沈澱物於真空乾 燥。形成之產物係化合物8。 實施例9(化合物9之合成) 化合物9係依據第9圖所示之反應製備。 對-漠紛2.63克(15毫莫耳)、二溴已^.22克(5毫莫耳) 及無水碳酸鉀1.38克(10毫莫耳)之混合物溶於丙酮,且加熱 迴流。迴流8小時後,添加水以終結進一步之反應。混合物 與50毫升之醚(3次)混合以萃取有機沈澱物。沈澱物依序以 2M氣氧化納溶液、鹽水清洗,然後,於無水MgS〇4乾燥。 移除剩餘溶劑後’粗製產物於乙醇内再結晶,形成化合物 9 ’重1.15克(46重量%產率),且經測量之光譜係ιΗ 25 200925244 NMR(CDC13, 400MHz) 5[ppm]: 7.369-7.347(d, 4H, J=8.8Hz), 7.776-7.754(d, 4H, J=8.8Hz), 3.929(t, 4H), 1.803(m, 4H), 1.533(m, 4H)。13C NMR (CDC13, 400MHz) δ (ppm):158.429, 132.409, 116.548, 112.885, 68.299, 29.290, 25.982。 5 實施例10(化合物10之合成) 化合物10係表示為3F1-PEG2000,其係依據第10圖所 示之反應使用化合物2、3及4製備。化合物2(0.15克,0.25 毫莫耳)、化合物4 (1.103克,0.25毫莫耳)、四(三苯基膦) 鈀(50毫克,0.04毫莫耳)、含水之碳酸鈉(2M,1.24毫升), © 10 及曱苯(10.16毫升)之混合物被脫氧,然後,於氮氣下加熱 迴流。混合物攪拌4小時。其次,溶於1毫升甲苯内之0.103 克(0.18毫莫耳)之化合物3添加至混合物。混合物進一步撥 拌約2天,然後,冷卻至室溫。混合物内之有機溶劑被蒸發。 殘質溶於4毫升之二氣甲烷,且與100毫升之醚混合形成沈 15澱物。溶劑藉由離心處理而移除。沈澱方法重複3次。粗製 產物溶於二氣曱烷,且接受使用8k透析管之透析約丨週。然 後,溶液被冷凍乾燥,形成淡色粉末產物,其係化合物1〇。 〇 合成方法之產率係24重量%。 於化合物10,PEG區段係親水性,且其它區段係疏水 2〇性。化合物10分子内之親水性對疏水性單元之重量比例係 約4:卜水中之化合物1(^CAC係〇〇5毫克/毫升。 為自化合物1〇製備穩定之顆粒,1〇毫克之化合物1〇溶 於1〇毫升之水(等於2〇 CAC)。形成之溶液擾拌3天。膠束顆 粒於溶液中形成,其於貯存時保持穩定6個月。 26 200925244 實施例11(化合物11之合成) 5 ❹ 10 15 ❹ 20 化合物11係3F2-PEG2000,其係依據第11圖所示之反應 使用化合物4及6製備。化合物4(0.46克,1毫莫耳)、化合物 6(1.123克,0.25毫莫耳)、四(三苯基膦)纪(50毫克,〇·〇4毫 莫耳)、含水之碳酸鈉(2M,1.24毫升),及甲苯(10.16毫升) 之混合物被脫氧’然後,於氮氣下加熱迴流。混合物授拌2 天,然後’冷卻至室溫。混合物内之有機溶劑被蒸發。殘 質溶於20毫升之二氯甲烷,且與800毫升之醚混合形成沈搬 物。溶劑藉由離心處理移除。沈澱方法重複3次。粗製產物 浴於一風甲烧,且接受使用8k透析管之透析約1週。溶液冷 /東乾燥形成淡色粉末產物,其係化合物11。此方法之產率 係50%。如化合物1〇,化合物u内之親水性對疏水性區段 之重量比例係約4:1。 化合物11之重量平均分子量(Mw)及數平均分子量(Mn) 係以凝膠滲透色譜分析術(GPC)分析為基礎且pEG被作為 校正用之標準物而決定,發現個別係4123及3969。Gpc結 果指不每一化合物11分子僅含有—其間pEG側鏈附接至芴 基之嵌段。 化合物11之CAC係使用動態光散射(DLS)技術於室溫 於水溶液㈣量,且發現飢〗毫克/毫升。水中之化合㈣ 之CAC係0.10毫克/毫升。 為自化口物11製備穩定之顆教,1〇毫克之化合物出容 於1〇毫升之梢於1G CAC)。軸之減授拌3天 。膠束顆 粒於溶液中形成,其於貯存時保持敎6個月。 27 200925244 實施例12(化合物12之合成) 化合物12係5F3-PEG2000,其係依據第12圖所示之反 應使用化合物2、3及6製備。化合物2(0.23克,0.4毫莫耳)、 化合物3(0.25克’ 0.6毫莫耳)、化合物6(0.45克,0.1毫莫耳)、 5 四(三苯基膦)鈀(32毫克,0.028毫莫耳)、含水之碳酸鈉 (2M,0.88毫升),及甲苯(2.6毫升)之混合物被脫氧,然後, 於氮氣下加熱回流。混合物於迴流下2天,然後,冷卻至室 溫。混合物内之有機溶劑被蒸發,且殘質溶於20毫升之二 氣甲烷。溶液與800毫升之醚混合形成沈澱物。溶劑藉由離 10 心處理移除。沈澱方法重複3次。粗製產物溶於二氣甲烷, 且接受使用8k透析管之透析約一週。溶液被冷凍乾燥形成 淡色粉末產物,其係化合物12。此實施例之產率係46%。 化合物12内之親水性對疏水性單元之重量比例係約2.4:1。 化合物12之重量平均分子量(mw)及數平均分子量(Μη) 15係以GPC分析為基礎且PEG被作為校正用之標準物而決 定,發現個別係4409及3919。GPC結果指示每一化合物12 分子僅含有一其間PEG侧鏈附接至芴基之嵌段。 化合物12之CAC係使用DLS技術於室溫於水溶液内測 量,且發現係0.08毫克/毫升。 20 為自化合物12製備穩定之顆粒,10毫克之化合物12溶 於10毫升之水(等於12.5 CAC)。形成之溶液攪拌3天。膠束 顆粒於溶液中形成,其於貯存時保持穩定6個月。 實施例13(化合物13之合成) 化合物13 (PF1-PEG2000)係依據第丨3圖所示之反應使 200925244 用化合物1、2及6製備。此間使用之符號ρ及q代表整數。如 第13圖所示,P+q= 19。化合物1(〇.〇89克,0.18毫莫耳)、化 合物2(0.117克,0.2毫莫耳)、化合物6(0.0898克,〇.〇2毫莫 耳)、四(三苯基膦)把(2毫克,0.002毫莫耳)、含水之碳酸鈉 5 (2M,0.284毫升)及曱苯(1.15毫升)之混合物被脫氧,然 後,於氣氣下加熱迴流。混合物於迴流下2天,然後,冷卻 至室。混合物内之有機溶劑被蒸發,且殘質溶於4毫升之 二氯甲烷。溶液與100毫升之醚混合形成沈澱物。溶劑藉由 〇 離心作用移除。沈澱方法重複3次。粗製產物溶於二氣甲 1〇 烷,且接受使用l〇k透析管之透析約一週。然後,溶液被冷 凍乾燥,形成淡黃色粉末產物,化合物13。形成之產物具 有約85 nm之顆粒尺寸。此實施例之產率係14%。產物之測 量光譜係 1H NMR (CDC13, 400MHz) δ[ρριη]: 7.854(m,30H), 7.674(m, 90H), 3.643(m, 360H), 2.129(m, 80H), 1.414(m, 15 240H), 0.795(m,200H)。化合物13内之親水性對疏水性單元 之重量比例係約1:1.6。化合物13之CAC發現係0.008毫克/ ❹ 毫升。 化合物13之螢光及穩定性被測試。為了此目的,BV-2 細胞被培養2天。含有〇.3毫克/克之自化合物 2〇 13(PF1-PEG2000)形成之奈米顆粒之水溶液係如下般製 備。3毫克之化合物13溶於1.5毫升之THF形成起始溶液。起 始溶液以THF進一步稀釋至形成溶液之總體積係2毫升為 止。8毫升之去離子水於3小時期間緩慢添加至形成之溶 液。溶液被容納於一瓶子中。此瓶子以一張Kimwipes™衛 29 200925244 生紙覆蓋,使THF於3天期間蒸發。3天後水添加至 以調整最終溶液之濃度,其具有1〇毫升之總體積。最終溶 液含有約0.3毫克/克之化合物13(等於約4〇cac)。 溶液係以1:1〇㈣之比例添加至培養基。細胞於 基内維持6小時。其次,細胞以4%多聚甲搭固定2小時然 後’以PBS清洗3次。細胞於共輛焦顯微鏡下觀察。二批: 化合物13被用於此測試。第一批之化合物⑽新製備。第 二批之化合物13係於室溫貯存於水溶液内至少6個月。於二 情況,經固定之細胞顯示相似強度之螢光。 於另-測試,經培養之BV_細胞於培養2天後沈降。其 次,含有自如上所述之化合物13形成之顆粒之水溶液添加 至培養基。不同測試係以不同批次物進行,其中,培養基 内之水溶液濃度個別係1%、2%、5%、1〇%,或2〇% (v/v)。 1520 It is contemplated that the fluorescent particles formed by the above exemplary methods are soluble in hydrazine and in aqueous environments such as water, and (4) for a longer period of time, up to 6 months, exhibit stable glory release ( See, for example, Example I3) below. In comparison, when the nanoparticles of the nanometer size are used with similar sites: the weight ratio of the hydrophilic segment to the hydrophobic segment in the particle is formed when the amphiphilic molecule outside the range of w to 18 200925244 4:1 is formed. The particles may be unstable in water, and their performance such as fluorescence detection is expected to deteriorate in a relatively short period of time (such as from 1 day to one week). For example, an amphiphilic graft polymer 2,7-monobromo-9,9(6-polyethylene glycol-hexyl)anthracene and 2_bromo-9,9(6,_polyethylene glycol_hexyl) 5苟It has been found to be unstable in water. The weight ratio of the hydrophilic segment to the hydrophobic segment in the two compounds is about 10:1. Conversely, the test results show that when the weight ratio is in the range of about 1:4 to about 4:1, and the concentration of the grafted molecules in the second solution is from about 1 to about 1000 CAC (such as from about 10 to about 100 CAC). At the time, the test sample grafted molecules formed fluorescent particles that were observed to be stable in the aqueous phase at an extended period of time (such as more than 6 months). In a particular embodiment, the backbone of the grafted molecule comprises oligosaccharides or polyfluorenes, and the side chains comprising PEC^PEG units can have any suitable size or weight. The grafted precursor of the grafted molecule can be coupled via a Suzuki coupling reaction. The weight ratio of PEG to oligo or polyfluorene in the trowel is about 1:4 to 4:1, or about 3:7 to about 7.3. In the first solution, the organic solvent may be terpene or dihalogen methane. The first product can be added to the water by dripping when the mixed solution is stirred. The organic agent can be removed by evaporation. The formed particles may have a size ranging from several nanometers to several micrometers. The first solution and the particles formed in the water will exhibit a strong glory emission. Fluorescence can be measured using a fluorescence spectrometer or a confocal spectrometer. The intense fluorescence exhibited by such particles can be used for imaging or detection applications, for biological applications. For example, the particles can be attached to a particular ligand. The vector may be a nucleotide, a single strand of DNA, a double stranded DNA, a single strand of RNA, a biguanide-15 τντ a , a peptide, a protein, a hormone, an antibody, a receptor, an antigen, an antigen 19 200925244 determinant, a nucleic acid binding protein, Molecules, enzyme substrates or analogs thereof, avidin, streptavidin, biotin, monosaccharides, polysaccharides, and the like. Particles with specific ligands can be used to calibrate specific cells or organisms. When the particle size is generally in the nanometer range, it can be easily absorbed by cells or organisms. The particles may also be prepared to be compatible with the selected environment, such as surrounding cells. For example, the components of the granules can be selected such that the presence of the granules does not undesirably act, such as being toxic to the cells. EXAMPLES Example 1 (Synthesis of Compound 1) ® 10 Compound 1 is 2,7-dibromo~(9,9-dihexyl)anthracene prepared according to the reaction shown in Figure 1. 2,7-Dibromoindole (9.72 g, 30 mmol, obtained from Sigma-Aldrich) was added to 8 〇〇c of aqueous sodium hydroxide (54.3 ml, 50%), tetrabutylammonium bromide (1 82 Gram, 5.63 millimolar), and a mixture of 1_bromohexane (25.36 ml '180 mmol). The mixture was cooled to room temperature after 5 hours of mixing. The mixture is mixed with dioxane to extract the reaction product. The organic layer was washed sequentially with water, aqueous HC1, water, and brine. The layer washed with 0 was dried using anhydrous MgS04. The remaining solvent and excess 1-bromohexane were removed. The residue was purified by vermiculite gel column chromatography using hexane as the eluent. The purified product contained a white solid in a weight of 20 14.55 g, corresponding to a yield of 98.6% by weight. The measured spectrum of the white solid: NMR (CDC13, 400MHz) δ[ρρπι]: 7.513 (m,6H), 1.908 (m, 4H), 1.119 (m, 12H), 0.782 (t, 6H), 0.583 ( m, 4H), confirmed product containing compound 1 '2,7-di-di-(9,9-dihexyl) 3⁄4. Example 2 (Synthesis of Compound 2) 20 200925244 Compound 2 is 2,7-bis(4,4,5,5-tetramethyl-U,2-dioxaborane-2-yl) 9,9-dihexyl芴, which is prepared according to the reaction shown in Figure 2, using compound i. 2.46 g (5 mmol) of Compound 1 was added to THF (5 mL) to form a solution. The solution was cooled to -78. (: 15 ml (18 mmol) of n-butyllithium (1.2 M 'obtained from AldrichTM) was added to the solution to form a mixture. The mixture was mixed for 1 hour and the solution temperature was maintained at _78〇c. 2_Isopropoxy-4,4,5,5-tetradecyl-1,3,2-dioxaborane (2.7 ml, 12.98 mmol) was added rapidly to the mixture. Warm to room temperature, and stir for 10 overnight. The mixture is poured into water. The reaction product in the mixture is extracted with ether. The extraction method is repeated 3 times. The extracted organic layer is mixed and washed with brine and anhydrous magnesium sulfate. Drying. The remaining solvent was removed by rotary evaporation. The residue was purified by column chromatography (ethyl acetate:hexane = 1: 15). The purified product contained 1.823 g of white solids. Yield of % by weight.) The measured spectrum of the white solid is 1H NMR (CDC13, 400 MHz) 8 [ppm]: 7.793 (d, 2H, J = 7.6 Hz), 7.742 (s, 2H), 7.725 (d , 2H, J=7.6Hz), 1.995 (m, 4H), 1.386 (s, 24H), 1.064 (m, 12H), 0.740 (t, 6H), 0.546 (m, 4H), confirm the product compound 2 ' 2,7- (4,4,5,5-tetramethyl-1,3,2-dioxaborane-2-yl) 9,9-dihexyl 20 芴. Example 3 (Synthesis of Compound 3) Compound 3 Series 2 -Bromo-(9,9-dihexyl)anthracene, which is synthesized according to the reaction shown in Figure 3. 2-bromoindole (12.25 g, 50 mmol) is added to 8 (TC of aqueous sodium hydroxide) 91 ml, 50%), a mixture of tetrabutylammonium bromide (3.03 g, 9.38 21 200925244 mmol) and 1-bromohexane (42.3 ml, 300 mmol). After stirring for 4 hours, the mixture was cooled to After extraction with di-methane, the mixed organic layer was washed successively with water, aqueous HC1, water, and brine, and then dried in anhydrous MgSCU. The remaining solvent was removed from the dried layer and excess 5 1 After the bromohexane, the residue was purified by vermiculite gel column chromatography using hexane as the eluent. The product formed contained 20. 3 g (97 wt% yield) of pale yellow liquid product. And the measured spectrum is 4 NMR (CDC13, 400MHz) 5 [ppm]: 7.681 (m, 1H), 7.57 (d, J = 7.7 Hz, 1H), 7.45 (m, 2H), 7.35 (m, 3H) ), 1.95 (m,4H), 1.09 (m, 12H), 0.79 (t, 10 】=7.1 along, 611), 0. 62 (111, 411). The product is the compound 3,2-bromo-(9,9-dihexyl)anthracene. Example 4 (Synthesis of Compound 4) Compound 4 is 2-(4,4,5,5-tetramethyl-1,3,2-dioxaboran-2-yl)-9,9-dihexylfluorene It is prepared by using Compound 3 according to the reaction shown in Fig. 4. 62 g (15 mmol) of compound 3 was mixed with 100 ml of anhydrous THF to form a solution. 22.5 ml of n-BuLi (27 mmol) was added to this solution at -78 °C. The solution was stirred for 1 hour before adding 2_isopropoxy-4 4 5 5 -tetramethyl H2-dioxaborane (3.9 mL, 18.75 mmol). The resulting mixture was mixed overnight. Then, water is added to further the reaction. The reaction product in the mixture 20 was extracted three times with di-methane (100 ml). The extracted organic layer was washed with brine dried over anhydrous MgSO.sub.4 and then concentrated in vacuo. The concentrated layer was subjected to column chromatography (elite gel, ethyl acetate: hexane = 1 : 20) to yield a product of 5.83 g (yield: 8.45 wt.). The measured spectrum of the product is 1H NMR (CDC13, 400MHz) δ[ρριη]: 7.812 (m, 200925244 1H), 7.747 (m, 3H), 7.322 (m, 3H), 7.322 (m, 3H), 1.990 ( m, 4H), 1.39 (s, 12H), 1.023 (m, 12H), 0.752 (m, 6H), 0.597 (m, 4H), confirmed product 4, 2-(4,4,5,5- Tetramethyl-1,3,2-dioxaborane-2-yl)-9,9-dihexylfluorene. 5 Example 5 (Synthesis of Compound 5) Compound 5 is 2,7-dibromo-9,9-bis(6,-bromohexyl) 3⁄4, which is prepared according to the reaction shown in Figure 5. 2,7-Dibromoindole (0.972 g, 3 mmol) was added to aqueous potassium hydroxide (60 ml, 50%) at 75 ° C, tetrabutylammonium bromide (0.198 g, 0.6 mmol). 'And a mixture of 1,6-two-seat (7.32 g, 30 mmol). After stirring for 15 minutes, the mixture was cooled to room temperature. After extraction with methylene chloride, the combined organic layers were washed successively with water, aqueous HCl, water, and brine, and then dried over anhydrous MgS04. After removing the remaining solvent and excess 1,6-dibromohexane, 'residue was analyzed by vermiculite gel column chromatography using hexane: gas (v/v: 9:1) as eluent And purified. The product formed contained 15 white solids of 1.47 g (75 wt% yield), and the measured spectrum was 1 NMR (CDC13, 400 MHz) δ (ppm): 7.433-7.535 (m, 6H), 3.294 ❹ ( t, 4H), 1.923 (m, 4H), 1.652-1.687 (m, 4H), 1.203 (m, 4H), 1.083 (m, 4H), 0.587 (m, 4H), confirm the product compound 5, 2, 7-Dibromo-9,9-bis(6,-bromohexyl)anthracene. 20 Example 6 (Synthesis of Compound 6) Compound 6 is 2,7-dibromo-9,9(6'-polyethylene glycol-hexyl)anthracene, which is based on the reaction shown in Figure 6 using Compound 5 preparation. Sodium hydride (0.9 g, 40 mmol) and dry THF (30 mL) were placed in a three-neck 150 ml flask under argon. Then, PEG (8 g, 4 mmol) 23 200925244 in THF (50 ml) was added dropwise to /BZL. As shown in Figure 6, the molecular weight of peg used is 2000 Daltons, expressed as PEG2000 or PEG2_. However, it is understood that PEG2000 is used for testing purposes, and in various embodiments of the invention, the weight of PEG can vary. 5 The resulting mixture was stirred for 4 hours. Next, 0.65 g (1 mmol) of Compound 5 was added to the flask. The mixture in the flask was stirred at room temperature for about 1 week. In this case, water is added by dripping to terminate the further reaction. The organic solvent in the mixture was evaporated, and the residue was dissolved in 20 ml of di-methane and 4 ml of methanol. The solution was mixed with 500 ml of ether to form a precipitate. The precipitate was collected by centrifuging the solvent with ❹10. The precipitate was further purified by repeating the above method 3 times, and then dried under vacuum. The product formed is compound 6. Example 7 (Synthesis of Compound 7) Compound 7 is 2-bromo-9,9-bis(6,-bromohexyl)anthracene which is prepared according to the reaction of Figure 7. 2-bromoindole (4.9 g, 20 mmol) was added to a 75 ° C 15 aqueous potassium hydroxide (400 mL, 50%), tetrabutyl bromo bromide (1.32 g, 4 mM) and 1 a mixture of 6-dibromohexane (48.8 g, 200 mmol). After stirring for 15 minutes, the mixture was cooled to room temperature. After extraction with digas methane, the mixed organic layer was washed successively with water, aqueous hydrazine α, water, and brine, and then dried in anhydrous MgS〇4. Remove the remaining solvent and excess sputum, after the 6_two deserts have been burned, the residue is eluted by lithography/gas imitation (v:v = 9:1) by Shi Xishi gel column chromatography. Purified by liquid. The product was a pale yellow liquid, weighed 8 6 g (75 wt% yield), and the measured spectrum is iH NMR (CDCl3, 4 〇〇 MHz) δ (ppm): 7.669 (m, 1H), 7.548 (m, 1H) , 7.453 (m, 2H), 7.322 (m, 3H), 3.280 (t, 4H), 1.943 (m, 4H), 1.657 (m, 4H), 1.193 24 200925244 (m,4Η),1·073 (m , 4Η)' 0.604 (m, 4Η), confirming the product is a compound 7,2-di-9,9-bis(6'-indolyl)indole. Example 8 (Synthesis of Compound 8) 5 φ 10 15 ❹ 20 Compound 8 is a 2-bromo-9,9(6'-polyethylene glycol-hexyl) fluorene which is used according to the reaction shown in Figure 8 7 and synthesized. Sodium hydride (0.96 g &apos; 40 mmol) and anhydrous THF (3 mL) were placed in a three-neck 150 ml flask under argon. PEG (8 g '4 mmol) in thf (50 ml) was added dropwise in the chamber. The mixture was disturbed for 4 hours. Next, '0.57 g (1 mmol) of compound 7 was added to the mixture. The mixture was further stirred at room temperature for about one week. Water was then added dropwise to the flask to terminate the further reaction. The solution was evaporated to remove the THF. The remaining mixture was dissolved in 20 ml of di-methane and 4 ml of methanol, and then mixed with 500 ml of ether to form a precipitate. The solvent in the mixture is removed by centrifugation. The above precipitation method was repeated 3 times. The precipitate formed was dried under vacuum. The product formed is compound 8. Example 9 (Synthesis of Compound 9) Compound 9 was prepared according to the reaction shown in Figure 9. A mixture of 2.63 g (15 mmol), dibromide (22 mmol) and anhydrous potassium carbonate 1.38 g (10 mmol) was dissolved in acetone and heated to reflux. After refluxing for 8 hours, water was added to terminate the further reaction. The mixture was mixed with 50 ml of ether (3 times) to extract an organic precipitate. The precipitate was washed successively with 2M gas oxidized sodium solution, brine, and then dried in anhydrous MgS〇4. After removal of the remaining solvent, the crude product was recrystallized from ethanol to give compound 9' weighs 1.15 g (46 wt% yield), and the measured spectrum is ι 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 -7.347 (d, 4H, J = 8.8 Hz), 7.776-7.754 (d, 4H, J = 8.8 Hz), 3.929 (t, 4H), 1.803 (m, 4H), 1.533 (m, 4H). 13C NMR (CDC13, 400 MHz) δ (ppm): 158.429, 132.409, 116.548, 112.885, 68.299, 29.290, 25.982. 5 Example 10 (Synthesis of Compound 10) Compound 10 is represented by 3F1-PEG2000, which was prepared according to the reaction shown in Figure 10 using Compounds 2, 3 and 4. Compound 2 (0.15 g, 0.25 mmol), Compound 4 (1.103 g, 0.25 mmol), tetrakis(triphenylphosphine) palladium (50 mg, 0.04 mmol), aqueous sodium carbonate (2M, 1.24) ML), a mixture of 10 and toluene (10.16 ml) was deoxygenated and then heated to reflux under nitrogen. The mixture was stirred for 4 hours. Next, 0.103 g (0.18 mmol) of Compound 3 dissolved in 1 ml of toluene was added to the mixture. The mixture was further stirred for about 2 days and then cooled to room temperature. The organic solvent in the mixture is evaporated. The residue was dissolved in 4 ml of di-methane and mixed with 100 ml of ether to form a precipitate. The solvent is removed by centrifugation. The precipitation method was repeated 3 times. The crude product was dissolved in dioxane and subjected to dialysis for about 8 weeks using an 8k dialysis tube. The solution is then lyophilized to form a pale powder product which is the compound 1 〇. The yield of the 〇 synthesis method was 24% by weight. In compound 10, the PEG segment is hydrophilic and the other segments are hydrophobic. The weight ratio of the hydrophilicity to the hydrophobic unit in the molecule of the compound 10 is about 4: Compound 1 in water (^CAC system 〇〇 5 mg/ml. For the preparation of stable particles from the compound 1 ,, 1 〇 of the compound 1 The hydrazine was dissolved in 1 mL of water (equal to 2 〇 CAC). The resulting solution was scrambled for 3 days. The micelle granules were formed in solution and remained stable for 6 months during storage. 26 200925244 Example 11 (Compound 11 Synthesis) 5 ❹ 10 15 ❹ 20 Compound 11 is a 3F2-PEG2000 prepared according to the reaction shown in Figure 11 using Compounds 4 and 6. Compound 4 (0.46 g, 1 mmol), Compound 6 (1.123 g, a mixture of tetrakis(triphenylphosphine) (50 mg, 〇·〇 4 mmol), aqueous sodium carbonate (2M, 1.24 ml), and toluene (10.16 ml) was deoxygenated' then The mixture was heated to reflux under nitrogen, and the mixture was stirred for 2 days, then 'cooled to room temperature. The organic solvent in the mixture was evaporated. The residue was dissolved in 20 ml of dichloromethane and mixed with 800 ml of ether to form a sink. The solvent was removed by centrifugation. The precipitation method was repeated 3 times. The product bath was simmered in a wind and subjected to dialysis using an 8k dialysis tube for about 1 week. The solution was cold/east dried to form a pale powder product which was compound 11. The yield of this method was 50%. The weight ratio of the hydrophilicity to the hydrophobic segment in the compound u is about 4: 1. The weight average molecular weight (Mw) and the number average molecular weight (Mn) of the compound 11 are based on gel permeation chromatography (GPC) analysis. And pEG was determined as a standard for calibration, and individual lines 4123 and 3969 were found. The Gpc result means that not 11 molecules of each compound only contain - the block in which the pEG side chain is attached to the thiol group. The CAC of compound 11 is used. Dynamic Light Scattering (DLS) technique was applied to the aqueous solution at room temperature (IV) and found to be hunger mg/ml. The compound of CCA in water (4) was 0.10 mg/ml. For the preparation of self-chemical substance 11, a stable teaching, 1 〇 mg The compound was excreted in 1 liter of tip at 1G CAC). The shaft is reduced for 3 days. The micelle granules are formed in solution and are kept for 6 months during storage. 27 200925244 Example 12 (Synthesis of Compound 12) Compound 12 is a 5F3-PEG2000 which was prepared according to the reaction shown in Figure 12 using Compounds 2, 3 and 6. Compound 2 (0.23 g, 0.4 mmol), Compound 3 (0.25 g '0.6 mmol), Compound 6 (0.45 g, 0.1 mmol), 5 (triphenylphosphine) palladium (32 mg, 0.028) A mixture of aqueous sodium carbonate (2M, 0.88 ml) and toluene (2.6 mL) was deoxygenated and then heated to reflux under nitrogen. The mixture was refluxed for 2 days and then cooled to room temperature. The organic solvent in the mixture was evaporated and the residue was dissolved in 20 ml of methane. The solution was mixed with 800 ml of ether to form a precipitate. The solvent is removed by treatment from 10 hearts. The precipitation method was repeated 3 times. The crude product was dissolved in digas methane and subjected to dialysis using an 8 k dialysis tube for approximately one week. The solution was lyophilized to form a pale powder product which was compound 12. The yield of this example was 46%. The weight ratio of hydrophilic to hydrophobic units in compound 12 is about 2.4:1. The weight average molecular weight (mw) and number average molecular weight (?n) of the compound 12 were determined based on GPC analysis and PEG was determined as a standard for calibration, and individual lines 4409 and 3919 were found. The GPC results indicate that each compound 12 molecule contains only one block in which the PEG side chain is attached to the thiol group. The CAC of Compound 12 was measured in aqueous solution at room temperature using DLS technique and found to be 0.08 mg/ml. 20 To prepare stable granules from compound 12, 10 mg of compound 12 was dissolved in 10 ml of water (equal to 12.5 CAC). The resulting solution was stirred for 3 days. Micelle particles are formed in solution which is stable for 6 months during storage. Example 13 (Synthesis of Compound 13) Compound 13 (PF1-PEG2000) was prepared according to the reaction shown in Figure 3, using 200925244 with Compounds 1, 2 and 6. The symbols ρ and q used here represent integers. As shown in Figure 13, P+q=19. Compound 1 (〇.〇89 g, 0.18 mmol), Compound 2 (0.117 g, 0.2 mmol), Compound 6 (0.0898 g, 〇.〇2 mmol), tetrakis(triphenylphosphine) (2 mg, 0.002 mmol), a mixture of aqueous sodium carbonate 5 (2M, 0.284 ml) and toluene (1.15 ml) was deoxygenated and then heated to reflux under a gas atmosphere. The mixture was refluxed for 2 days and then cooled to the chamber. The organic solvent in the mixture was evaporated and the residue was dissolved in 4 mL of dichloromethane. The solution was mixed with 100 ml of ether to form a precipitate. The solvent is removed by centrifugation. The precipitation method was repeated 3 times. The crude product was dissolved in dioxane and subjected to dialysis for 1 week using a l〇k dialysis tube. Then, the solution was freeze-dried to form a pale yellow powder product, Compound 13. The resulting product has a particle size of about 85 nm. The yield of this example was 14%. The measured spectrum of the product is 1H NMR (CDC13, 400MHz) δ[ρριη]: 7.854 (m, 30H), 7.674 (m, 90H), 3.643 (m, 360H), 2.129 (m, 80H), 1.414 (m, 15 240H), 0.795 (m, 200H). The weight ratio of the hydrophilicity to the hydrophobic unit in the compound 13 is about 1:1.6. The CAC of Compound 13 was found to be 0.008 mg / 毫升 ml. The fluorescence and stability of Compound 13 were tested. For this purpose, BV-2 cells were cultured for 2 days. An aqueous solution containing 〇.3 mg/g of nanoparticles formed from the compound 2〇 13 (PF1-PEG2000) was prepared as follows. 3 mg of compound 13 was dissolved in 1.5 ml of THF to form a starting solution. The initial solution was further diluted with THF to a total volume of 2 ml of the forming solution. 8 ml of deionized water was slowly added to the formed solution over a period of 3 hours. The solution is contained in a bottle. The bottle was covered with a piece of KimwipesTM 29 200925244, allowing the THF to evaporate during 3 days. After 3 days, water was added to adjust the concentration of the final solution, which had a total volume of 1 mL. The final solution contained about 0.3 mg/g of compound 13 (equal to about 4 〇cac). The solution was added to the medium in a ratio of 1:1 〇 (iv). The cells were maintained in the base for 6 hours. Next, the cells were fixed with 4% polymethylation for 2 hours and then washed 3 times with PBS. The cells were observed under a co-focus microscope. Two batches: Compound 13 was used for this test. The first batch of compound (10) was newly prepared. The second batch of compound 13 was stored in aqueous solution at room temperature for at least 6 months. In the second case, the fixed cells show fluorescence of similar intensity. In another test, the cultured BV_ cells were sedimented after 2 days of culture. Next, an aqueous solution containing particles formed from the compound 13 as described above is added to the medium. The different test lines were carried out in different batches, wherein the concentration of the aqueous solution in the medium was 1%, 2%, 5%, 1%, or 2% (v/v), respectively. 15

對每一批次物,BV2細胞之細胞活性係於12小時之間隔測 量四次(即,於添加後之12、24、48,及72小時)»代表性之 測量結果係顯示於第21圖。對於其間顆粒溶液之濃度係於 1%至5%之範圍之批次物,培養基内測量之細胞數量係隨時 間顯著增加。對於具較高濃度(10%及2〇%)之批次物,增加 較不顯著。此於顆粒溶液之溶劑係水時被預期。細胞數量 20顯著增加指示化合物13之螢光顆粒係無毒性,或對細胞僅 具有極低之毒性。 觀察到於細胞被活化後’細胞可吸收更多之自化合物 13形成之螢光顆粒。此暗示顆粒可作為用以遞送藥物或其 它物質至經選擇性活化之細胞/有機體之載劑。 30 200925244 實施例14(化合物η之合成) 化合物14係PF2-PEG2000 ’其係依據第14圖所示之反 應使用化合物1、2、6,及9製備。如同符號“p”及“q”,符 號η於此使用時亦代表整數。於第丨4圖,n之值可為1至 5 1〇〇,諸如,1至20,且p+q= 10。化合物1(〇 16克,〇·32毫 莫耳)、化合物2(0.28克,0.48毫莫耳)、化合物6(0.36克,0.08 毫莫耳)、化合物9(40毫克,〇.〇8毫莫耳)、四(三苯基膦) 纪(78毫克’ 〇.〇7毫莫耳)、含水之碳酸鈉(2Μ,〇 93毫升), 〇 及甲苯(3·72毫升)之混合物被脫氧,然後’於氮氣下加熱迴 10流。混合物於迴流下2天,然後,冷卻至室溫。有機溶劑被 蒸且殘質〉谷於10毫升之一氣曱院。溶液與400毫升之喊 混合形成沈;殿物。溶劑藉由離心處理移除。沈澱方法重複3 次。粗製產物溶於二氣曱烷,且接受使用10k透析管之透析 . 約一週。溶液被冷凍乾燥,形成淡黃色粉末產物,化合物 15 14。產物顆粒具有約154 nm之尺寸。產率係37重量%。化 合物14内之親水性對疏水性單元之重量比例係約丨力9。化 © 合物14之CAC發現係0.00032毫克/毫升。 含有自化合物14形成之顆粒之水溶液係使用如對於化 合物13所述者相同之程序且以化合物14取代化合物13而製 20 備。最終之水溶液含有約0.3毫克/毫升之化合物14(等於約 940 CAC)。最終溶液内之膠束顆粒於貯存時維持穩定6個 月。 實施例15(化合物15之合成) 化合物15係PF3-PEG2000,其係依據第15圖所示之反 31 200925244 應使用化合物1、2、6,及9製備。於第15圖’η可為1至100 ’ 諸如,1至20,且p+q= 4。化合物1(0.16克,0.32毫莫耳)、 化合物2(0.28克,0.48毫莫耳)、化合物6(0.36克,0.08毫莫 耳)、化合物9(40毫克,0_08毫莫耳)、四(三苯基膦)鈀(64.1 5 毫克,0.055毫莫耳)、含水之碳酸鈉(2M,0.88毫升),及甲 苯(3.毫升)之混合物被製備。混合物如實施例14所述般處 理。形成之產物係淡色粉末產物,化合物15。產物顆粒具 有約178 nm之尺寸。產率係21重量%。化合物15中之親水 性對疏水性單元之重量比例係約5:2。化合物15之CAC發現 Ο 10 係0.0004毫克/毫升。 含有自化合物15形成之顆粒之水溶液係使用如對於化 合物13所述者相同之程序且以化合物15取代化合物13而製 備。最終之水溶液含有約0.3毫克/毫升之化合物15(等於約 750 CAC)。最終溶液内之膠束顆粒於貯存時維持穩定6個 15 月。 實施例16 BV-2細胞被培養2天,然後,藉由添加不同濃度之刺激 〇 劑,脂多醣,活化24小時。含有自化合物13形成之螢光顆 粒之水溶液係如實施例13所述般製備。溶液添加至細胞培 20養基。溶液對培養基之體積比係1:1〇〇。來自培養基之螢光 係使用共軛成像技術監測。觀察到當刺激強度增加(於沃刺 激劑後)時,自細胞之螢光發射變得更強,指示更多之螢光 顆粒已由活化之細胞吸入。 如可瞭解般,上述實施例之合成路徑可被改質或一般 32 200925244For each batch, the cell viability of BV2 cells was measured four times at 12-hour intervals (ie, 12, 24, 48, and 72 hours after addition). Representative measurements are shown in Figure 21. . For batches in which the concentration of the particulate solution is in the range of 1% to 5%, the number of cells measured in the medium is significantly increased over time. For batches with higher concentrations (10% and 2%), the increase was less significant. This is expected when the solvent of the granule solution is water. A significant increase in the number of cells 20 indicates that the fluorescent particles of Compound 13 are non-toxic or have only very low toxicity to cells. It was observed that after the cells were activated, the cells could absorb more fluorescent particles formed from the compound 13. This suggests that the particles act as a carrier for delivering the drug or other substance to the selectively activated cells/organisms. 30 200925244 Example 14 (Synthesis of Compound η) Compound 14 is a PF2-PEG2000' which was prepared according to the reaction shown in Figure 14 using Compounds 1, 2, 6, and 9. Like the symbols "p" and "q", the symbol η also represents an integer when used herein. In Fig. 4, the value of n may be 1 to 5 1 , such as 1 to 20, and p + q = 10. Compound 1 (〇16 g, 〇·32 mmol), Compound 2 (0.28 g, 0.48 mmol), Compound 6 (0.36 g, 0.08 mmol), Compound 9 (40 mg, 〇.〇8 m Mole), tetrakis(triphenylphosphine) (78 mg '〇.〇7 mmol), aqueous sodium carbonate (2 Μ, 〇93 ml), a mixture of hydrazine and toluene (3·72 ml) was deoxygenated Then 'heated back to 10 streams under nitrogen. The mixture was refluxed for 2 days and then cooled to room temperature. The organic solvent was steamed and the residue was sown in a 10 ml broth. The solution is mixed with 400 ml shout to form a sink; The solvent is removed by centrifugation. The precipitation method was repeated 3 times. The crude product was dissolved in dioxane and subjected to dialysis using a 10 k dialysis tube. About one week. The solution was lyophilized to form a pale yellow powder product, compound 15 14 . The product particles have a size of about 154 nm. The yield was 37% by weight. The weight ratio of the hydrophilicity to the hydrophobic unit in the compound 14 is about 丨9. The CAC of the compound 14 was found to be 0.00032 mg/ml. The aqueous solution containing the particles formed from the compound 14 was prepared by the same procedure as described for the compound 13 and substituting the compound 14 for the compound 13. The final aqueous solution contained about 0.3 mg/ml of compound 14 (equal to about 940 CAC). The micelle particles in the final solution remained stable for 6 months during storage. Example 15 (Synthesis of Compound 15) Compound 15 is PF3-PEG2000, which was prepared according to the reverse 31 200925244 shown in Figure 15 using Compounds 1, 2, 6, and 9. In Fig. 15, 'n may be 1 to 100' such as 1 to 20, and p + q = 4. Compound 1 (0.16 g, 0.32 mmol), Compound 2 (0.28 g, 0.48 mmol), Compound 6 (0.36 g, 0.08 mmol), Compound 9 (40 mg, 0_08 mmol), A mixture of triphenylphosphine)palladium (64.1 5 mg, 0.055 mmol), aqueous sodium carbonate (2M, 0.88 mL), and toluene (3 mL) was prepared. The mixture was treated as described in Example 14. The product formed was a pale powder product, compound 15. The product particles have a size of about 178 nm. The yield was 21% by weight. The weight ratio of the hydrophilicity to the hydrophobic unit in the compound 15 is about 5:2. The CAC of Compound 15 found Ο 10 system 0.0004 mg/ml. The aqueous solution containing the particles formed from the compound 15 was prepared by the same procedure as described for the compound 13 and substituting the compound 15 for the compound 13. The final aqueous solution contained about 0.3 mg/ml of compound 15 (equal to about 750 CAC). The micelle particles in the final solution remained stable for 6 months at the time of storage. Example 16 BV-2 cells were cultured for 2 days and then activated by adding different concentrations of stimulating sputum, lipopolysaccharide, for 24 hours. An aqueous solution containing the fluorescent particles formed from Compound 13 was prepared as described in Example 13. The solution was added to the cell culture 20 nutrient. The volume ratio of the solution to the medium was 1:1 〇〇. Fluorescence from the medium was monitored using conjugate imaging techniques. It was observed that as the stimulation intensity increased (after the irritant), the fluorescence emission from the cells became stronger, indicating that more of the fluorescent particles had been inhaled by the activated cells. As can be appreciated, the synthetic path of the above embodiment can be modified or generally 32 200925244

化而製造依據本發明之各方面之其它接枝分子。例如,水 溶性螢光聚合物可一般依據第16圖所示之反應形成,且於 主幹内具有可撓性區段之聚合物可依據第Π圖所示之反應 製備。 5 對於第16圖所示之反應’ X、y、z、p、q,及η之值(其 表示整數)可改變。總和,p+q (=x+y+z),亦可改變。如所 瞭解,形成化合物13,x=9,y=10,z = 1 ;且於化合物13, 10 15 2〇 p=l,q=19,且1!=1。於不同實施例,p+q之值可改變,諸如, 2至200。具有不同之p+q總和之分子可藉由調整存在於反應 混合物内之反應物之相對之莫耳或重量比例而製備。 一般,形成穩定之奈米化顆粒之螢光聚合物可如下般 形成。適當量之化合物1、2,及6與四(三苯基膦)鈀、含水 之碳酸鈉,及曱苯混合形纽合物1合物内反應物之濃 度可改變。於-實施例,總反應物之濃度可為q i ML 〇 Μ。混合物可被脫氧,然後,於氮氣下加熱迴流。混合物 4於迴流下,且㈣-段延長之時間(諸如,2天至_,缺 後,冷卻至較低溫度(諸如,室溫)。使混合物内之有機溶劑 療發。殘質可溶於最小量之二氯r或另外之適合溶劑。 新溶液與適合量之魏切纽_。新紐_之體積 比可壯刚至1:。溶射藉由,諸如離心處理移除。 洗澱方法可被重複,諸如,3次。獲得之粗製產物可溶於二 氣甲域糾適合之_職劑,且可接受精(諸如^ 用他透析管卜段延長之時瞻如約3天至—週卜容液 «冷綠燥形絲終絲,其含有自所欲之接枝分子來 33 200925244 成之顆粒。顆粒之尺寸可藉由改變分子結構、分子量,或 溶液濃度而控制。 樣品化合物係依據第16圖之反應及如上之程序製備, 其中,試劑之濃度被選擇以使p=1且主幹單元之總數係18。 5形成化合物之C AC係使用D L S技術於室溫時於水溶液中測 量,且發現係0.008毫克/毫升。此樣品化合物之重量平均分 子量(Mw)及數平均分子量(Mn)係以Gpc分析為基礎且以 PEG作為校正之標準物而決定,且發現個別係19585及 9886。Mn之值亦係以NMR測量為基礎而計算,且發現係 10 9976。GPC結果指示樣品化合物分子僅含有一其間PEG側 鏈與苟基附接之嵌段。 為依據第17圖所示之反應製備化合物,相似之程序被 依循,但另外之化合物,化合物9,被包含於起始混合物内。 第Π圖中之符號a、b、c、d,及r亦代表整數。化合物9與所 15有其它組份間之莫耳比例可為1:100至1:2,諸如,1:5〇至 1:2。一般,p可為 1至10, q可為 m2〇〇, r(=d)可為 ι2〇, 且η可為1至1〇〇 ’諸如,1至2〇。a、b、c及d之值可依據所 欲之最終產物而選擇。如所瞭解,當r =〇時,第17圖之化人 物係與第16圖所示之化合物相同。於不同實施例,p+q之 2〇 總和可改變,諸如,2至200。 自依據第10或17圖所示之反應路徑製備之化合物形成 之顆粒亦可具有所欲之顆粒尺寸分佈。例如,如18、19及 20圖所示,水溶液内之化合物11、12或13之顆粒尺寸(有效 直徑)係約10至約300 nm。顆粒尺寸係以顆粒之透寸式電子 34 200925244 顯微術(TEM)為基礎而測量。第22及23圖顯示個別自化合物 10及化合物11形成之螢光顆粒之例示之ΤΕΜ圖像。用於 ΤΕΜ成像之樣品係如下般製備。9〇 pL之顆粒水溶液與1〇 μί 1% PTA水溶液藉由旋渴式混合。然後,一滴混合物置於 5 400_篩目之以碳塗覆之銅格柵上,且以空氣乾燥隔夜。第 22圖所示之顆粒具有1〇〇至2〇〇 nm之有效直徑,且第23圖所 示之顆粒具有範圍為10至20 nm及50至80 nm之有效直徑。 如先前所探討’依據本發明之實施例而製備之顆粒於 ® 水性環境能展現良好之穩定性。例如,顆粒可於水中保持 10 多於6個月之穩定。 此間使用之某些用辭可參考“Glossary of basic terms in polymer science (IUPAC Recommendations 1996)’’,Pure Appl. Chem.出版,1996,第68冊,編號12, 2287-2311頁而瞭解,其 全部内容在此被併入以供參考之用。 15 如所瞭解,本發明之實施例具有於不同領域及產業之 各種不同應用。例如,如上所述之接枝分子及顆粒可於許 響 多領域(諸如,生化領域)作為螢光探測器、標記,或標籤。 其等可用於藥物及基因之研究、細胞/微生物之成像、疾病 診斷、分析物檢測等。 2〇 於上未明確述及之此間所述之實施例之其它特徵、利 益及優點可由熟習此項技藝者自此說明内容及圖式而瞭 解。 當然,上述實施例僅係用於例示說明,且非用以限制。 所欲之實施例係容許型式、零件配置、細節,及操作順序 35 200925244 之許多改良。本發明係意欲使所有此等改良包含於如申咬 專利範圍所界定之範圍内。 玲 【圖式簡單說明】 5 第1至15圖係顯示例示本發明實施例 物之合成路徑之示意化學反應圖; 之個別特別化合 般合成 第16圖係顯示例示本發明實施例之聚合物 路徑之示意化學反應圖; 10 第17圖係顯示例示本發明實施例之於主幹具 區段之聚合物之一般合成路徑之示意化學反應圖· 第18至20圖係顯示不同化合物形成之經測 寸之圖; 可繞性 量之顆粒Other graft molecules in accordance with various aspects of the invention are made. For example, a water-soluble fluorescent polymer can generally be formed in accordance with the reaction shown in Figure 16, and a polymer having a flexible segment in the backbone can be prepared according to the reaction shown in Figure 。. 5 The value of the reaction 'X, y, z, p, q, and η (which represents an integer) shown in Fig. 16 can be changed. The sum, p+q (=x+y+z), can also be changed. As understood, compound 13 was formed, x = 9, y = 10, z = 1; and at compound 13, 10 15 2 〇 p = 1, q = 19, and 1 ! In various embodiments, the value of p+q can vary, such as from 2 to 200. Molecules having a different sum of p+q can be prepared by adjusting the relative molar or weight ratio of the reactants present in the reaction mixture. Generally, a fluorescent polymer forming stable nanoparticles can be formed as follows. The concentration of the reactants in the appropriate amounts of the compounds 1, 2, and 6 with the tetrakis(triphenylphosphine)palladium, the aqueous sodium carbonate, and the fluorene-benzene mixed complex may vary. In the examples, the concentration of the total reactants can be q i ML 〇 Μ. The mixture can be deoxygenated and then heated to reflux under nitrogen. Mixture 4 is refluxed and (4)-stage is extended for a period of time (such as 2 days to _, after cooling, to a lower temperature (such as room temperature). The organic solvent in the mixture is treated. The residue is soluble. The minimum amount of dichloro-r or another suitable solvent. The new solution and the appropriate amount of Weichin _. New _ volume ratio can be as strong as 1: Dissolution by, such as centrifugation removal. It is repeated, for example, 3 times. The obtained crude product is soluble in the two-dimensional corrective agent, and can be refined (such as the use of his dialysis tube to extend the time of the observation, such as about 3 days to - week) Bu Rong liquid «cold green dry silk end silk, which contains the desired grafting molecule 33 200925244 into particles. The size of the particles can be controlled by changing the molecular structure, molecular weight, or solution concentration. The reaction of Figure 16 and the above procedure are prepared, wherein the concentration of the reagent is selected such that p = 1 and the total number of backbone units is 18. 5 The C AC system forming the compound is measured in an aqueous solution at room temperature using the DLS technique. And found to be 0.008 mg / ml. This sample compound The average molecular weight (Mw) and the number average molecular weight (Mn) were determined based on Gpc analysis and PEG was used as the calibration standard, and individual lines 19585 and 9886 were found. The value of Mn was also calculated based on NMR measurement. And found to be 10 9976. The GPC results indicate that the sample compound molecule contains only one block in which the PEG side chain is attached to the thiol group. To prepare the compound according to the reaction shown in Figure 17, a similar procedure is followed, but in addition The compound, compound 9, is included in the starting mixture. The symbols a, b, c, d, and r in the figure also represent integers. The molar ratio between compound 9 and other components of 15 may be 1. :100 to 1:2, such as 1:5〇 to 1:2. Generally, p can be 1 to 10, q can be m2〇〇, r(=d) can be ι2〇, and η can be 1 to 1〇〇'such as, 1 to 2〇. The values of a, b, c, and d can be selected according to the desired final product. As understood, when r = ,, the figure of Figure 17 and the 16th The compounds shown in the figure are the same. In different embodiments, the sum of 2〇 of p+q can be changed, such as 2 to 200. From the reaction path according to Figure 10 or 17 The particles formed by the prepared compound may also have a desired particle size distribution. For example, as shown in Figures 18, 19 and 20, the particle size (effective diameter) of the compound 11, 12 or 13 in the aqueous solution is from about 10 to about 300. Nm. The particle size is measured on the basis of the particle-based electron 34 200925244 microscopy (TEM). Figures 22 and 23 show an exemplary image of the fluorescent particles formed from compound 10 and compound 11 individually. A sample for sputum imaging was prepared as follows. A 9 〇pL aqueous solution of the granules was mixed with a 1 〇μί 1% aqueous PTA solution by a thirst quenching. A drop of the mixture was then placed on a 5400 mesh stainless steel grid and dried overnight with air. The particles shown in Fig. 22 have an effective diameter of 1 〇〇 to 2 〇〇 nm, and the particles shown in Fig. 23 have effective diameters ranging from 10 to 20 nm and 50 to 80 nm. Particles prepared in accordance with embodiments of the present invention as previously explored exhibit good stability in an aqueous environment. For example, the granules can remain stable in water for more than 6 months. Some of the terms used herein can be found in "Glossary of basic terms in polymer science (IUPAC Recommendations 1996)", Pure Appl. Chem., 1996, vol. 68, No. 12, pages 2287-2311. The contents are hereby incorporated by reference. 15 As is understood, embodiments of the present invention have various applications in various fields and industries. For example, the grafted molecules and particles as described above can be used in many fields. (such as biochemical field) as a fluorescent detector, label, or label. It can be used for drug and gene research, cell/microbial imaging, disease diagnosis, analyte detection, etc. 2〇 is not explicitly mentioned above. Other features, advantages, and advantages of the embodiments described herein will be apparent to those skilled in the art from the The embodiments are a number of modifications of the permissible type, part configuration, details, and sequence of operations 35 200925244. The present invention is intended to include all such improvements in the scope of the patent application. In the range of the present invention, the first embodiment of the present invention shows a schematic chemical reaction diagram illustrating the synthetic route of the embodiment of the present invention; Schematic chemical reaction diagram of the polymer route; 10 Figure 17 shows a schematic chemical reaction diagram illustrating the general synthetic route of the polymer of the backbone section of the embodiment of the present invention. Figures 18 to 20 show the formation of different compounds. Measured inch chart

尺 第21圖係經測量之細胞數之線條圖; 第22圖係自例示本發明實施例之樣品化合物 光顆粒之透射式電子顯微術(TEM)圖像;且 开&gt; 成之螢 15 第23圖係自例示本發明實施例之另一樣品化合物 之螢光顆粒之透射式電子顯微術(TEM)圖像。 【主要元件符號說明】 形成 (無)Figure 21 is a line drawing of the measured number of cells; Figure 22 is a transmission electron microscopy (TEM) image of the sample compound light particles of the embodiment of the present invention; and opening &gt; Figure 23 is a transmission electron microscopy (TEM) image of fluorescent particles illustrating another sample compound of an embodiment of the present invention. [Major component symbol description] Formation (none)

3636

Claims (1)

200925244 十、申請專利範圍: 1. 一種形成勞光顆粒之方法,包含: 提供一包含水、有機溶劑,及溶於該有機溶劑之兩親性 分子之溶液,該兩親性分子包含複數個形成一分子主幹 5 之主幹單元,及複數個與該分子主幹接枝之側鏈,且每 一該側鏈係以至少一側鏈單元形成,該分子内之至少一 該側鏈單元係親水性,且至少三個該主幹單元係疏水性 及螢光性,該分子内之親水性之主幹單元及側鏈單元對 疏水性者之重量比例係約1:4至約4:1,該溶液内之該親水 10 性分子之濃度係約1至約1000 CAC,其中,該CAC係該 溶液内之該兩親性分子之臨界聚結濃度,及 自該溶液移除該有機溶劑,因而使該兩親性分子形成具 有約10nm至約10微米之外圍尺寸之該顆粒。 2. 如申請專利範圍第1項之方法,其中,於該溶液内之該兩 15 親性分子之該濃度係約10至約100CAC。 3. 如申請專利範圍第1或2項之方法,其中,該溶液係藉由 使水與一包含該有機溶劑及該兩親性分子之先質溶液混 合而製備。 4. 如申請專利範圍第1或2項之方法,其中,該移除包含藉 20 由蒸發使該有機溶劑自該溶液移除。 5. 如申請專利範圍第1或2項之方法,其中,該溶液具有約2 至約12之pH,且係於約0至約80 °C之溫度。 6. 如申請專利範圍第1或2項之方法,其中,該重量比例係 約3:7至約7:3。 37 200925244 7. 如申請專利範,_項之方法,其中,該主幹單元包 含芴單元,且該侧鏈包含聚乙二醇。 8. 如申請專利範圍第1或2項之方法,其中,該主幹單元包 含芳撐基、雜芳樓基、芳#基乙賴基、雜芳縣乙稀 5 躲、方撑基乙撲基,或雜芳撑基乙樓基單元,或其衍 生物。 - 9. 如申請專利範圍第8項之方法,其中,該主幹單元包含— ‘ 以统基、虎氧基、稀基、块基、炫基石夕烧基、芳基石夕烷 基方基、雜芳基、芳基氧、雜芳基氧、烧基硫基、烧基 〇 1〇 胺基、二烧基胺基、芳基胺基、二芳基胺基、芳基喊、 雜芳基键、芳基硫喊、雜芳基硫謎、_素、氰基、硝基、 #基、亞硫酿基、續酿基,或全敦烧基,或包含雜芳基 之胺基取代之單元。 10. 如申請專利範圍第項之方法,其中,該主幹單元包 15 含苯撐基、嚷吩撺基、螺旋二苟撲基、節并场樓基、咣 啶撐基、二吡啶撐基、咔唑撐基、茚并咔唑撐基苯并 嘍唑撐基,或噁二唑撐基單元,或其衍生物。 〇 U.如申請專利範圍第1或2項之方法,其中,(丨)至少一該主 幹單元係與乙烯撐基或乙撐基聯接,(2)其中,至少二該 2〇 主幹單元係經由單碳鍵、曱撐基,或選自〇、S、N、Si, 及P之原子彼此聯接。 12.如申請專利範圍第丨或2項之方法,其中,該主幹單元包 含連接二疏水性及螢光性之主幹單元之可撓性基,該可 撓性基係親水性或疏水性。 38 200925244 13. 如申請專利範圍第1或2項之方法,其中,該側鏈單元包 含聚乙二醇、聚乙二亞胺、聚醯胺、聚乙烯基吡咯烷酮、 聚丙烯酸、聚乙烯基醇、聚賴氨酸,或其衍生物。 14. 如申請專利範圍第1或2項之方法,其中,至少一該側鏈 5 係經由單碳鍵、單磷鍵、醚基、硫醚基、胺基、亞胺基、 矽烷基、酯基、硫酯基、醯胺基,或醯亞胺基與該主幹 鍵結。 15. 如申請專利範圍第1或2項之方法,其中,該兩親性分子 具有化學式,200925244 X. Patent application scope: 1. A method for forming Laoguang particles, comprising: providing a solution comprising water, an organic solvent, and an amphiphilic molecule dissolved in the organic solvent, the amphiphilic molecule comprising a plurality of forms a backbone unit of a molecular backbone 5, and a plurality of side chains grafted to the backbone of the molecule, and each of the side chains is formed by at least one side chain unit, at least one of the side chain units in the molecule being hydrophilic, And at least three of the backbone units are hydrophobic and fluorescent, and the weight ratio of the hydrophilic backbone unit and the side chain unit to the hydrophobic in the molecule is about 1:4 to about 4:1, and the solution is in the solution. The concentration of the hydrophilic 10 molecule is from about 1 to about 1000 CAC, wherein the CAC is the critical coalescence concentration of the amphiphilic molecule in the solution, and the organic solvent is removed from the solution, thereby enabling the parent The sex molecules form the particles having a peripheral dimension of from about 10 nm to about 10 microns. 2. The method of claim 1, wherein the concentration of the two 15 amphiphilic molecules in the solution is from about 10 to about 100 CAC. 3. The method of claim 1 or 2, wherein the solution is prepared by mixing water with a precursor solution comprising the organic solvent and the amphiphilic molecule. 4. The method of claim 1 or 2, wherein the removing comprises removing the organic solvent from the solution by evaporation. 5. The method of claim 1 or 2, wherein the solution has a pH of from about 2 to about 12 and is at a temperature of from about 0 to about 80 °C. 6. The method of claim 1 or 2, wherein the weight ratio is from about 3:7 to about 7:3. 37 200925244 7. The method of claim 1, wherein the backbone unit comprises a unit and the side chain comprises polyethylene glycol. 8. The method of claim 1 or 2, wherein the main unit comprises an arylene group, a hetero-aromatic base, a aryl #基乙赖基, a hetero-compound, a thief 5, a chelating group Or a heteroarylylene group unit, or a derivative thereof. - 9. The method of claim 8, wherein the backbone unit comprises - 'in the base group, alkoxy group, a dilute group, a block group, a radiant group, an aryl group, an alkyl group, a hetero group Aryl, aryloxy, heteroaryloxy, alkylthio, alkyl hydrazide, dialkylamino, arylamino, diarylamine, aryl, heteroaryl , aryl sulfonium, heteroaryl sulfide, _ cyano, cyano, nitro, # yl, sulfinyl, continuation, or decyl, or an amine substituted unit containing a heteroaryl . 10. The method of claim 1, wherein the main unit package 15 comprises a phenylene group, a fluorenyl group, a helix fluorenyl group, a cleavage group, an acridine group, a dipyridyl group, An oxazolidinyl, an indolocarbazolylbenzoxazole group, or an oxadiazolylene unit, or a derivative thereof. The method of claim 1 or 2, wherein at least one of the backbone units is coupled to a vinylene group or an ethylene group, and (2) wherein at least two of the two backbone units are via A single carbon bond, an oxime group, or an atom selected from the group consisting of ruthenium, S, N, Si, and P is bonded to each other. 12. The method of claim 2, wherein the backbone unit comprises a flexible group linking the two hydrophobic and fluorescent backbone units, the flexible substrate being hydrophilic or hydrophobic. The method of claim 1 or 2, wherein the side chain unit comprises polyethylene glycol, polyethylenediamine, polyamine, polyvinylpyrrolidone, polyacrylic acid, polyvinyl alcohol , polylysine, or a derivative thereof. 14. The method of claim 1 or 2, wherein at least one of the side chains 5 is via a single carbon bond, a monophosphorus bond, an ether group, a thioether group, an amine group, an imido group, a decyl group, an ester A thiol group, a guanidino group, or a quinone imine group is bonded to the backbone. 15. The method of claim 1 or 2, wherein the amphiphilic molecule has a chemical formula, 其中,p、q、r,及η係整數,p係1至10,q係1至200,r 係0至20,且η係1至20。 16. 如申請專利範圍第15項之方法,其中,r=0。 15 17. 如申請專利範圍第1或2項之方法,其中,該兩親性分子 具有化學式,Wherein p, q, r, and η are integers, p is 1 to 10, q is 1 to 200, r is 0 to 20, and η is 1 to 20. 16. The method of claim 15, wherein r=0. 15 17. The method of claim 1 or 2, wherein the amphiphilic molecule has a chemical formula, 其中,p、q,及η係整數,η係1至20,且p+q係2至200。 18. 如申請專利範圍第17項之方法,其中,p+q = 4或10。 19. 如申請專利範圍第1或2項之方法,其中,該兩親性分子 具有化學式, 39 20 200925244Wherein p, q, and η are integers, η is 1 to 20, and p+q is 2 to 200. 18. The method of claim 17, wherein p+q = 4 or 10. 19. The method of claim 1 or 2, wherein the amphiphilic molecule has a chemical formula, 39 20 200925244 20·如申請專利範圍第19項之方法,其中,n=l,且p = q=l 或p = q = 2。 5 21.如申請專利範圍第1或2項之方法,其中,該兩親性分子 具有化學式,20. The method of claim 19, wherein n = 1 and p = q = 1 or p = q = 2. 5. The method of claim 1 or 2, wherein the amphiphilic molecule has a chemical formula, 22. 如申請專利範圍第1或2項之方法,其中,該兩親性分子 係藉由下述形成: 10 形成該主幹單元之先質,該先質包含疏水性螢光基; 使親水性基接枝至該先質,形成經接枝之先質;及 聯接該經接枝之先質,因而形成該兩親性分子。 23. 如申請專利範圍第22項之方法,其中,該聯接包含經由 偶合反應而聯接。 15 24.如申請專利範圍第22項之方法,其中,該聯接包含經由 鈴木偶合反應、格里那偶合反應、史提勒偶合反應、海 克偶合反應、Sologashira偶合反應、氧化聚合反應、還 原聚合反應,或聚縮合反應之聯接。 25. —種水溶性螢光顆粒,包含依據申請專利範圍第1項之方 200925244 法形成之該分子。 26. —種分子,包含: 複數個形成一分子主幹之主幹單元;及 複數個與該分子主幹接枝之侧鏈,且每一該側鏈係以至 5 ❹ 10 15 ❹ 20 少一側鏈單元形成, 其中’該分子内之至少一該側鏈單元係親水性,且至少 三個該主幹單元係疏水性及螢光性,且 其中,該分子内之親水性之主幹單元及側鏈單元對疏水 性者之重量比例係約1:4至約4:1。 27. 如申請專利範圍第26項之分子,其中,該重量比例係約 3:7至約7:3。 28. 如申請專利範圍第26或27項之分子,其中,該主幹單元 包含场單元’且該側鏈包含聚乙二醇。 29_如申請專利範圍第26或27項之分子,其中,該主幹單元 包含芳撐基、雜芳撐基、芳撐基乙烯撐基、雜芳撐基乙 烯撐基、芳撐基乙撐基,或雜芳撐基乙撐基單元,或其 衍生物。 30.如申請專利範圍第29項之分子,其中,該主幹單元包含 一以烷基、烷氧基、烯基、炔基、烷基矽烷基、芳基矽 烷基芳基、雜芳基、芳基氧、雜芳基氧、烷基硫基、烷 基胺基、二烷基胺基、芳基胺基、二芳基胺基、芳基醚、 雜芳基醚、芳基硫醚、雜芳基硫醚、齒素、氰基、硝基、 羰基、亞硫醯基、磺醯基,或全氟烷基,或包含雜芳基 之胺基取代之單元。 41 200925244 31.如申請專利範圍第26或27項之分子,其中,該主幹單元 包含苯撐基、噻吩撐基、螺旋二芴撐基、茚并芴撐基、 吡啶撐基、二吡啶撐基、咔唑撐基、茚并咔唑撐基、笨 并嚷唾樓基,或α惡二β坐撲基單元,或其衍生物。 5 32·如申請專利範圍第26或27項之分子,其中,(1)至少一該 主幹單元係與乙烯撐基或乙撐基聯接,(2)其中,至少二 該主幹單元係經由單碳鍵、甲撐基,或選自Ο、S、Ν、 Si,及Ρ之原子彼此聯接。 33.如申請專利範圍第26或27項之分子,其中,該主幹單元 10 包含連接二疏水性及螢光性之主幹單元之可撓性基,該 可撓性基係親水性或疏水性。 34·如申請專利範圍第26或27項之分子,其中,該側鏈單元 包含聚乙二醇、聚乙二亞胺、聚醯胺、聚乙烯基吡咯烷 酮、聚丙烯酸、聚乙烯基醇、聚賴氨酸,或其衍生物。 15 35.如申請專利範圍第26或27項之分子,其中,至少一該側 鏈係經由單碳鍵、單磷鍵、醚基、硫醚基、胺基、亞胺 基、矽烷基、酯基、硫酯基、醯胺基,或醯亞胺基與該 主幹鍵結。 36.如申請專利範圍第26項之分子,具有化學式,22. The method of claim 1 or 2, wherein the amphiphilic molecule is formed by: 10 forming a precursor of the stem unit, the precursor comprising a hydrophobic fluorescent group; The base is grafted to the precursor to form a grafted precursor; and the grafted precursor is coupled to form the amphiphilic molecule. 23. The method of claim 22, wherein the coupling comprises coupling via a coupling reaction. 15 24. The method of claim 22, wherein the coupling comprises via a Suzuki coupling reaction, a Grignard coupling reaction, a Stirling coupling reaction, a Heck coupling reaction, a Sologashira coupling reaction, an oxidative polymerization reaction, a reduction polymerization The reaction, or the coupling of a polycondensation reaction. 25. A water-soluble fluorescent particle comprising the molecule formed according to the method of the 200925244 method of claim 1. 26. A molecule comprising: a plurality of backbone units forming a molecular backbone; and a plurality of side chains grafted to the backbone of the molecule, each of the side chains being up to 5 ❹ 10 15 ❹ 20 less side chain units Forming, wherein: at least one of the side chain units in the molecule is hydrophilic, and at least three of the backbone units are hydrophobic and fluorescent, and wherein the hydrophilic backbone unit and the side chain unit pair in the molecule The weight ratio of the hydrophobic is from about 1:4 to about 4:1. 27. The numerator of claim 26, wherein the weight ratio is from about 3:7 to about 7:3. 28. The molecule of claim 26 or 27, wherein the backbone unit comprises a field unit&apos; and the side chain comprises polyethylene glycol. [29] The molecule of claim 26, wherein the backbone unit comprises an arylene group, a heteroaryl group, an arylene vinylene group, a heteroarylvinylene group, an arylethylene group Or a heteroarylylenediyl unit, or a derivative thereof. 30. The molecule of claim 29, wherein the backbone unit comprises an alkyl group, an alkoxy group, an alkenyl group, an alkynyl group, an alkyl decyl group, an aryl decyl aryl group, a heteroaryl group, an aromatic group. Oxygen, heteroaryloxy, alkylthio, alkylamino, dialkylamino, arylamine, diarylamine, aryl ether, heteroaryl ether, aryl sulfide, miscellaneous An aryl sulfide, a dentate, a cyano group, a nitro group, a carbonyl group, a sulfinyl group, a sulfonyl group, or a perfluoroalkyl group, or a unit substituted with an amine group containing a heteroaryl group. 41. The molecule of claim 26, wherein the backbone unit comprises a phenylene group, a thiophene group, a helical diamylene group, an indenoindolyl group, a pyridinylene group, a dipyridyl group. , oxazolylene, indolocarbazole, stupid and sulphate, or alpha oxa beta sulphonyl unit, or a derivative thereof. 5 32. The molecule of claim 26 or 27, wherein (1) at least one of the backbone units is coupled to an ethylene or ethylene group, and (2) wherein at least two of the backbone units are via a single carbon A bond, a methylene group, or an atom selected from the group consisting of ruthenium, S, osmium, Si, and iridium is coupled to each other. 33. The molecule of claim 26 or 27, wherein the backbone unit 10 comprises a flexible group connecting two hydrophobic and fluorescent backbone units, the flexible substrate being hydrophilic or hydrophobic. 34. The molecule of claim 26 or 27, wherein the side chain unit comprises polyethylene glycol, polyethylenediamine, polyamine, polyvinylpyrrolidone, polyacrylic acid, polyvinyl alcohol, poly Lysine, or a derivative thereof. 15 35. The molecule of claim 26 or 27, wherein at least one of the side chains is via a single carbon bond, a monophosphorus bond, an ether group, a thioether group, an amine group, an imido group, a decyl group, an ester A thiol group, a guanidino group, or a quinone imine group is bonded to the backbone. 36. The numerator of claim 26, which has a chemical formula, 係0至20 ’且η係1至20。 200925244 37·如申請專利範圍第36項之分子,其中,r=0。 38·如申請專利範圍第26項之分子,具有化學式, Ο 10 PEG〇CeH12. .CeH12OPEGIt is 0 to 20 ' and η is 1 to 20. 200925244 37. The numerator of claim 36, wherein r=0. 38. If the molecule of claim 26 is a chemical formula, Ο 10 PEG〇CeH12. .CeH12OPEG CgH13 CeH13 o(ch2)6o.CgH13 CeH13 o(ch2)6o. 其中,P、q,及n係整數,n係1至20,且p+q係2至200 39. 如申請專利範圍第38項之分子,其中,p+q = 4或10。 40. 如申請專利範圍第26項之分子,具有化學式, pegoc6h12. .c6h12opegWherein, P, q, and n are integers, n is 1 to 20, and p+q is 2 to 200. 39. The molecule of claim 38, wherein p+q = 4 or 10. 40. If the numerator of claim 26 is of a chemical formula, pegoc6h12. .c6h12opeg CeHl3 c®Hl3 c6H13,、c6H13 其中,P、q,及n係整數,讀^至沈,且p+q係2至2〇〇。 41. 如申請專利範圍第40項之分子,其中,n=1,且p = q=1 或P = q = 2。 42. 如申請專利範圍第26項之分子,具有化學式,細〜C6H13 。一,c6h12〇pegCeHl3 c®Hl3 c6H13,, c6H13 wherein P, q, and n are integers, read ^ to sink, and p + q is 2 to 2 〇〇. 41. The numerator of claim 40, wherein n = 1, and p = q = 1 or P = q = 2. 42. The numerator of claim 26, which has the chemical formula, fine ~ C6H13. One, c6h12〇peg ceHi3- '〇6ηι3 43.-種水溶性㈣難,包含_料利範圍第 子。 26項之分 申-月專利範圍第25或43項之顆粒,包含—對選擇之標 靶具特定親和力之配位體。 申請專利範圍第44項之顆粒,其中,該配位體係選自 和素生物素、抗體、抗原,及DNA,且其中,該標 43 200925244 靶係選自標靶分子、細胞,及有機體。ceHi3- '〇6ηι3 43.-A kind of water-soluble (four) is difficult, including _ material range range. 26 items The particles of the 25th or 43rd patent of the patent-month patent include - a ligand with a specific affinity for the selected target. The particle of claim 44, wherein the coordination system is selected from the group consisting of a biotin, an antibody, an antigen, and a DNA, and wherein the target is a target molecule, a cell, and an organism. 4444
TW097138687A 2007-10-17 2008-10-08 Water-soluble fluorescent material with balanced hydrophilicity and hydrophobicity TW200925244A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SG2007/000351 WO2009051560A1 (en) 2007-10-17 2007-10-17 Water-soluble fluorescent material with balanced hydrophilicity and hydrophobicity

Publications (1)

Publication Number Publication Date
TW200925244A true TW200925244A (en) 2009-06-16

Family

ID=40567644

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097138687A TW200925244A (en) 2007-10-17 2008-10-08 Water-soluble fluorescent material with balanced hydrophilicity and hydrophobicity

Country Status (3)

Country Link
JP (1) JP2011500916A (en)
TW (1) TW200925244A (en)
WO (1) WO2009051560A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2164988B1 (en) 2006-10-06 2016-02-17 Sirigen Inc. Fluorescent methods and materials for directed biomarker signal amplification
EP2499213B1 (en) 2009-11-09 2019-01-16 University Of Washington Center For Commercialization Functionalized chromophoric polymer dots and bioconjugates thereof
EP4322238A3 (en) 2010-01-19 2024-05-15 Sirigen II Limited Novel reagents for directed biomarker signal amplification
EP3434642A1 (en) * 2010-10-18 2019-01-30 University of Washington through its Center for Commercialization Chromophoric polymer dots
JP2014515052A (en) * 2011-03-28 2014-06-26 ヒタチ ケミカル リサーチ センター インコーポレイテッド Network conjugated polymer with improved solubility
US9797840B2 (en) 2011-11-28 2017-10-24 University Of Washington Through Its Center For Commercialization Highly fluorescent polymer nanoparticle
US8835000B2 (en) * 2011-12-23 2014-09-16 General Electric Company High-density fluorescent dye clusters
CN104487097B (en) 2011-12-30 2019-01-18 华盛顿大学商业中心 Chromophoric polymers point with narrow emission
WO2013116614A1 (en) 2012-02-03 2013-08-08 University Of Washington Through Its Center For Commercialization Polyelectrolyte-coated polymer dots and related methods
US20150175747A1 (en) * 2012-07-25 2015-06-25 National University Of Singapore Highly Emissive Far-Red/Near-Infrared Fluorescent Conjugated Polymer-Based Nanoparticles
US20140302516A1 (en) 2013-03-14 2014-10-09 University Of Washington Through Its Center For Commercialization Polymer dot compositions and related methods
WO2014198669A1 (en) * 2013-06-10 2014-12-18 Luxcel Biosciences Limited An oxygen sensitive material, and use thereof to sense oxygen in three-dimensional spaces
WO2015006714A1 (en) * 2013-07-11 2015-01-15 University Of Washington Through Its Center For Commercialization Fluorinated polymer dots
CN103804659B (en) * 2014-02-17 2016-09-21 中国科学院化学研究所 A kind of thieno with poly glycol monomethyl ether side chain [3,4-b] thiophene conjugated polymer material, its preparation method and application thereof
CN104004004B (en) * 2014-04-23 2015-12-02 华中师范大学 A kind of is the compound sending white light, the preparation and application of the isocyanide bridge chain gold of skeleton based on fluorenes
EP3215515A1 (en) 2014-11-03 2017-09-13 Life Technologies Corporation Dibenzosilole monomers and polymers and methods for their preparation and use
KR102558780B1 (en) 2016-04-15 2023-07-26 베크만 컬터, 인코포레이티드 Photoactive macromolecules and uses thereof
BR102019025989A2 (en) 2018-12-14 2020-06-23 Beckman Coulter, Inc. MODIFICATION OF POLYMERIC DYES AND APPLICATIONS
CN114539537B (en) * 2022-02-21 2023-06-06 中化国际(控股)股份有限公司 Adhesive for electrode material of lithium ion battery and preparation method thereof
WO2023177853A1 (en) * 2022-03-17 2023-09-21 Markushin Yuriy Enhancement compositions and uses thereof
CN114933693B (en) * 2022-06-17 2023-08-22 嘉应学院 Conjugated polymer material and preparation method and application thereof
CN115094379B (en) * 2022-07-04 2024-01-12 昆明理工大学 One-dimensional polyfluorene chain and preparation method thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001481D0 (en) * 2000-01-21 2000-03-15 Theryte Ltd System for delivering a medicament
GB0100760D0 (en) * 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
GB0100761D0 (en) * 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
US7241512B2 (en) * 2002-04-19 2007-07-10 3M Innovative Properties Company Electroluminescent materials and methods of manufacture and use
JPWO2005121203A1 (en) * 2004-04-14 2008-04-10 有限会社金沢大学ティ・エル・オー Hybrid body of conjugated polymer and metal salt showing high fluorescence quantum yield, method for producing the same, and fluorescent light emitting material using the same
JPWO2005100437A1 (en) * 2004-04-14 2008-03-06 有限会社金沢大学ティ・エル・オー Polyfluorene derivatives exhibiting unique luminescence and process for producing the same
US8173996B2 (en) * 2004-10-11 2012-05-08 Cambridge Display Technology Limited Polar semiconductor hole transporting material
EP1857489A4 (en) * 2005-03-09 2010-06-23 Toray Industries Microparticle and pharmaceutical composition
US8067506B2 (en) * 2005-08-30 2011-11-29 Agency For Science, Technology And Research Water-soluble fluorescent particle comprising entangled fluorescent polymer and amphiphilic molecule

Also Published As

Publication number Publication date
JP2011500916A (en) 2011-01-06
WO2009051560A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
TW200925244A (en) Water-soluble fluorescent material with balanced hydrophilicity and hydrophobicity
Liu et al. Syntheses and applications of dendronized polymers
Hammer et al. Dimensional evolution of polyphenylenes: expanding in all directions
Yue et al. Sequential “click” approach to polyhedral oligomeric silsesquioxane-based shape amphiphiles
Zhang et al. Synthesis of shape amphiphiles based on functional polyhedral oligomeric silsesquioxane end-capped poly (L-lactide) with diverse head surface chemistry
Harada et al. Polymeric rotaxanes
Chakraborty et al. Synthesis and optical properties of a rod− coil diblock copolymer with polyoxometalate clusters covalently attached to the coil block
US8394914B2 (en) Functional polyglycolide nanoparticles derived from unimolecular micelles
He et al. Facile construction of metallo-supramolecular poly (3-hexylthiophene)-block-poly (ethylene oxide) diblock copolymers via complementary coordination and their self-assembled nanostructures
US8324358B2 (en) Polymer compositions and uses thereof
Zhang et al. On-surface single molecule synthesis chemistry: a promising bottom-up approach towards functional surfaces
Jiang et al. Tetraphenylethene-functionalized polyethylene-based polymers with aggregation-induced emission
Xu et al. “Rod–coil” copolymers get self-assembled in solution
Bauer et al. Functionalised polyphenylene dendrimers and their applications
Zhang et al. Rationally controlling the self-assembly behavior of triarmed POSS–organic hybrid macromolecules: from giant surfactants to macroions
Xu et al. A facile synthetic route to multifunctional poly (3-hexylthiophene)-b-poly (phenyl isocyanide) copolymers: from aggregation-induced emission to controlled helicity
Li et al. Autofluorescent Polymers: 1 H, 1 H, 2 H, 2 H-Perfluoro-1-decanol Grafted Poly (styrene-b-acrylic acid) Block Copolymers without Conventional Fluorophore
Zaquen et al. Profluorescent PPV-based micellar system as a versatile probe for bioimaging and drug delivery
Reese et al. New methods in polymer brush synthesis: Non-vinyl-based semiflexible and rigid-rod polymer brushes
JPWO2011162366A1 (en) Water-soluble polymer and water-soluble nanoparticle composite
Bandyopadhyay et al. Hyperbranched polymers for biomedical applications
Wang et al. Deciphering structure–functionality relationship of polycarbonate-based polyelectrolytes by AIE technology
Wang et al. Self-assembly of giant bottlebrush block copolymer surfactants from luminescent organic electronic materials
Zhu et al. Understanding the seeded heteroepitaxial growth of crystallizable polymers: the role of crystallization thermodynamics
Matsumoto et al. Synthesis and properties of aromatic polyamide dendrimers with polyhedral oligomeric silsesquioxane cores